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ABSTRACT
IDENTIFICATION OF TYPE THREE SECRETION SYSTEM EFFECTORS LINKED TO
CLINICAL AND ENVIRONMENTAL PREVALENCE OF
VIBRIO PARAHAEMOLYTICUS
By
Sarah Eggert
University of New Hampshire
Vibrio parahaemolyticus is an emergent human pathogen that is the leading cause of
seafood-borne bacterial infections in the United States and worldwide. Recently, clinical
prevalence of V. parahaemolyticus has increased in the United States, especially from the North
Atlantic Ocean. The majority of clinical isolates of V. parahaemolyticus harbor a hemolysin gene
(tdh and/or trh) and a Type III Secretion System (T3SS)-containing mobile Vibrio Pathogenicity
Island (VPaI). The VPaIs are evolutionary related yet distinct. These VPaIs include VPaIα (tdh+),
VPaIβ (trh+), and a mosaic VPaIγ (tdh+/trh+). Strains harboring VPaIα cause the most infections
globally, whose major effectors are known. In the United States, in particular from the North
Atlantic, human infections with V. parahaemolyticus are predominantly caused by strains
harboring the relatively uncharacterized VPaIγ. There are four major VPaIγ lineages in V.
parahaemolyticus strains of North Atlantic, identified by the tdh allele they harbor. Strains
harboring tdh3-VPaIγ are isolated most clinically, though strains harboring tdh5-VPaIγ are
environmentally predominant. Using a dual approach of bioinformatics and bioassays, in this study
we identify five novel T3SS2 effectors on VPaIγ. We provide evidence that suggests a V.
parahaemolyticus population-based contribution towards its pathogenicity and environmental
prevalence. Patterns of recombination in toxin orthologs from tdh3-VPaIγ and tdh5-VPaIγ indicate

vii

that the surrounding population is a major contributor to the content of these VPaIs. The divergence
seen in these orthologs were assessed for contribution towards their effectiveness in pathogenesis
or environmental fitness. Our predatory grazing assay suggests that one effector may have evolved
for survival against eukaryotic predators in the environment. Utilizing bioassays to assess toxicity
and virulence, we found evidence that four of the VPaIγ orthologs likely contribute to the tdh3VPaIγ clinical prevalence. This work lays the foundation for understanding VPaIγ effector fitness
benefits in relation to their environment and population.
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CHAPTER I: INTRODUCTION
Vibrio parahaemolyticus
Vibrio parahaemolyticus is a gram-negative, halophilic bacterium found in brackish water
throughout the world. V. parahaemolyticus usually exists in a free-swimming state throughout the
water column in marine, estuarine, and coastal environments, but it also attaches to animate and
inert surfaces underwater such as suspended solids, sediments, shellfish, phytoplankton and
zooplankton, fish, and crustaceans 1–5. V. parahaemolyticus is an emergent human pathogen and
is the leading seafood-borne bacterial pathogen in the United States and worldwide. Food
poisoning caused by V. parahaemolyticus is generally caused by consuming raw, mishandled, or
undercooked seafood, including crab, shrimp, shellfish, lobster, ﬁsh, and oysters 6,7. Due to their
filter-feeding mechanisms, shellfish, especially oysters, can concentrate bacteria, including V.
parahaemolyticus, up to 100-fold higher than the surrounding water 6,8–11.

Pathogenic Vibrio spp. and their epidemiology
The genus Vibrio, collectively called Vibrios, belong to the Gammaproteobacteria class of
bacteria and are members of the Vibrionaceae family 4. They are ubiquitous in aquatic
environments, and though mostly harmless, some species, or more accurately, some strains of these
species, cause disease in humans and other animals 4. Vibriosis is a human illness caused by
Vibrios that do not harbor the cholera toxin. Many bacteria of the Vibrio genus can cause vibriosis
including most notably Vibrio vulnificus, Vibrio alginolyticus and V. parahaemolyticus

4,8,12–14

,

with the latter three species contributing to the highest amount of human illnesses in the United

1

States 15. Historically, Vibrio cholerae is the most well-known pathogenic Vibrio species since it
is the causal agent of the disease cholera 16,17. Cholera is associated with contaminated water and
poor sanitization, causes severe diarrhea and dehydration, and has caused seven pandemics since
1817 4. The Centers for Disease Control and Prevention (CDC) monitors V. cholerae infections
separately from other vibriosis cases due to it high infection rate and death toll 16,17.
V. parahaemolyticus is estimated to cause 45,000 of the 80,000 vibriosis illnesses each year in
the United States,15 and is the leading cause of seafood-borne bacterial infections in the United
States and worldwide

15,18,19

. Infection with V. parahaemolyticus can take on three forms:

gastroenteritis, wound infections, and, rarely, lethal septicemia 18. Wound infections occur through
the exposure of open wounds to seawater containing V. parahaemolyticus and are most common
among fishermen followed by those partaking in recreational aquatic activities

6,8,20–22

. These

wound infections can lead to life-threatening septicemia to immunocompromised individuals 6,23
and require hospitalization and in rare cases can lead to death

2,8,18,24

or necrotizing fasciitis

resulting in widespread tissue damage 20,21,25.
The most common form of V. parahaemolyticus infection is gastroenteritis, caused by
consumption of raw, undercooked, or mishandled seafood that is contaminated with pathogenic
strains 1,6,7,9,10,20,22. V. parahaemolyticus-induced gastroenteritis is typically mild and self-limiting,
lasting for 2–10 days

6,7

. Symptoms include acute dysentery, abdominal pain, watery diarrhea,

nausea, vomiting, fever, and chills 6,7,26–28. Pathological changes can vary from mild destruction of
the jejunum and ileum, and gastric inﬂammation, to severe cases including internal organ damage
(liver, spleen, lung congestion, etc.) 6. In rare cases, septicemia can result if V. parahaemolyticus
crosses the intestinal epithelium 25. Due to the self-limiting nature of gastroenteritis, infection with
V. parahaemolyticus is often under-reported and most commonly treated at home with oral
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rehydration 10,18. If reported, antibiotics may be prescribed 6. There have been very few studies on
non-human V. parahaemolyticus infections. Recent studies reported the damage to the shrimp
aquaculture industry from V. parahaemolyticus causing Acute Hepatopancreatic Necrosis Disease
(AHPND), also known as Early Mortality Syndrome (EMS), in penaeid shrimp 29–31.

Human infection with V. parahaemolyticus
V. parahaemolyticus is ubiquitous worldwide in many diverse populations, but only a
minority of members within these populations can infect and cause disease

3,19,32–35

. V.

parahaemolyticus infections typically occur seasonally during summer months (from June to
October in the northern hemisphere)

6

when surface water is warmest, facilitating total V.

parahaemolyticus populations to rise, including pathogen populations

36

. However, V.

parahaemolyticus infections still occur in cooler water and where there is a low abundance of V.
parahaemolyticus 19,37,38. Recurrent infections and outbreaks consistently occur in regions where
surface water remains cool throughout the year, in particular, the Pacific Northwest

22,35,39–41

. V.

parahaemolyticus infections occur worldwide, predominantly in countries with high levels of
seafood consumption 1.

Infections of V. parahaemolyticus in New England
Vibriosis cases in the United States have increased 120% from 1996 to 2014 (most current
data available from CDC as of May 24, 2020 43), with V. parahaemolyticus responsible for 6075% of cases

42,43

. This increase in reported cases also coincided with a drastic shift in regional

occurrence. Warmer regions, such as the Gulf of Mexico, shifted from 48% of vibriosis infections
to 36% 42. Interestingly, the cooler Northeast Atlantic coast region increased in vibriosis infections

3

from 3% in 1996 to 22% of vibriosis infections in 2014 42. Until recently, there was a long-held
belief based on the rare occurrence of illnesses, corroborated by low environmental abundance of
hemolysin-harboring members in the environment, that the environmental conditions of the
Northeastern US did not sustain pathogenic populations of V. parahaemolyticus 33,44. Except for a
large multi-state outbreak in 1998 from a non-indigenous strain of V. parahaemolyticus originating
from Southeast Asia in oysters harvested from Long Island Sound, V. parahaemolyticus has caused
few infections associated with shellﬁsh harvested from the cooler waters of the Northeastern US
22,26,45–47

. However, infections associated with Atlantic shellfish suddenly increased. This

coincided with warmer than usual ocean temperatures in the region, known to correlate with higher
densities of V. parahaemolyticus in the water column, and invasion of the Pacific Northwest
endemic pathogenic strain Sequence Type (ST) 36

8,22,48,49

. During this transitional period two

outbreaks occurred, one in New York in 2012, and the second in New York, Connecticut and
Massachusetts in 2013 49. Over the past decade, infection rates have continued to rise in the United
States despite the implementation of control measures, with the Northeast included. The cause of
this rise is unknown, but one hypothesis attributes this rise to the changing climate on pathogen
abundance and distribution 50.

Current molecular detection of pathogenic V. parahaemolyticus
Environmental surveillance/enumeration based on the conditionally adopted FDA BAM 51 for
V. parahaemolyticus includes quantifying the overall abundance of V. parahaemolyticus using the
thermolabile hemolysin (tlh) gene present in all strains, as well as the presence of the two
hemolysin genes tdh and trh, discussed further below, to quantify the number of “pathogenic” V.
parahaemolyticus. This “pathogenic” V. parahaemolyticus detection method does not provide an

4

accurate measure of the number of pathogenic V. parahaemolyticus nor the degree of pathogenicity
since 1) not all pathogenic V. parahaemolyticus harbor either tdh and/or trh, 2) not all V.
parahaemolyticus that harbor these hemolysins are pathogenic, and 3) V. parahaemolyticus
confers varying degrees of virulence despite the same tdh/trh profile, as inferred by clinical
prevalence 11,52–54. There is a significant gap in accurate detection of pathogenic strains, and it is
important to study V. parahaemolyticus populations to develop better detection tools for accurate
surveillance of the most important pathogenic lineages.

Bacterial Evolution
Bacteria can adapt to their environment under natural selection through the process of genome
evolution. This process of changing the content and organization of the bacterial genetic
information can occur through four general mechanisms: point mutations and gene conversions,
rearrangements (e.g., inversion or translocation), deletions of DNA, and insertions of foreign DNA
[e.g., plasmid integration, horizontal gene transfer (HGT), and transposition] 55,56. Gene loss and
recombination of acquired genes are primary forces by which bacteria adapt to new environments,
and these are critical forces on the evolution of microbial pathogens 32,55,57–62. Bacteria can acquire
accessory DNA such as plasmids, bacteriophages, transposons, integrative and conjugative
elements (ICEs), and genomic islands (GEIs), through the process of HGT 56. HGT is the transfer
of genetic material from one organism to another non-decedent organism 63. They can also acquire
homologous DNA harboring unique nucleotide variation by HGT, which can recombine with and
replace shared genetic content. These acquisitions can provide a fitness advantage beneficial to
bacteria under certain conditions such as adaptation to changing environmental conditions,
enhancing virulence, or immune evasion 32,34,56,57,64–66.

5

For HGT to occur efficiently, many bacteria can utilize conjugation machinery to either donate
or receive DNA directly from other bacteria or receive novel DNA by phage transduction. Vibrio
spp. have a rare mechanism, termed natural transformation, that enables them to uptake DNA from
their surrounding environment instead of direct transfer from other bacteria or phage 67–69. When
grown in the presence of chitin-based substrates, such as those abundant in marine environments,
Vibrio spp. turn on machinery to take up DNA from their environment 11,34. Natural transformation
occurs in environmental and pathogenic bacteria, including Acinetobacter spp., Bacillus subtilis,
Streptococcus

pneumoniae,

Neisseria

gonorrhoeae,

Pseudomonas

stutzeri,

Ralstonia

solanacearum, and Haemophilus inﬂuenzae 56.

Identification of potential virulence determinants of pathogenic V. parahaemolyticus
Tdh/Trh
Identification of the virulence effectors important in human gastrointestinal infection of V.
parahaemolyticus has been an active area of research for years

8,9,70

. Initially, many researchers

believed that the hemolysins, the thermostable direct hemolysin (Tdh), and thermostable related
hemolysin (Trh), were indicators for the virulence potential of V. parahaemolyticus since most
enteropathogenic V. parahaemolyticus harbored one or both of those genes, but these genes are
not essential for human disease 6,8,71–78.
In 1995 during the initial spread of the pandemic strain of V. parahaemolyticus, pathogenic
strains were identified by ß-hemolysis on specialized Wagatsuma Blood Agar known as Kanagawa
Phenomenon (KP)

73

. At that time, 95% clinical isolates of V. parahaemolyticus were KP+ (ß-

hemolytic), while 98–99% of the environmental samples were KP- (non-hemolytic) 1,6,75,79,80. This
KP+ hemolysis is caused by the hemolysin Tdh 6,7,24,72,81,82.

6

In addition to hemolysis, Tdh can also induce cytotoxicity, cardiotoxicity, and enterotoxicity
7,82

. Tdh is termed thermostable direct hemolysin due to its stability at 100°C 7,83. Tdh is a pore-

forming protein that alters ion flux in human cells, causing cytotoxicity. Tdh works in three
primary steps, it 1) binds to erythrocyte membrane or host cells 2) forms a ~2nm diameter
transmembrane pore which 3) disrupts the ion flux of Ca2+ and Cl− across the cell membrane,
increasing the osmotic pressure of the cell exceeding the upper limit for the cell beyond selfregulation, resulting in cell expansion and death 6,7. So far, there are seven distinct tdh alleles which
share a nucleotide sequence identity >96.7% 11,82,83.
Initially during the spread of pathogenic V. parahaemolyticus worldwide, the Wagatsuma
agar was a good screen for diarrhea-inducing V. parahaemolyticus during the original outbreak of
the pandemic strain, but then more KP- V. parahaemolyticus caused human sickness. The majority
of these KP- clinical isolates encode Trh 84–87. Trh is related to Tdh and plays a similar role as Tdh
in tissue pathoglogy 1,88. Trh is a pore-forming hemolysin and causes similar levels of hemolysis
as Tdh in vitro 6. It can form hemolytic zones on usual blood agar plates, but not on Wagatsuma’s
medium, and thus was used to identify KP- strains

83

. Wagatsuma’s medium was specially

formulated to produce distinctive ß-hemolysis in tdh-harboring V. parahaemolyticus due to the
specificity of erythrocyte source, pH, salt content, and carbohydrate content 89,90. Two trh alleles
have been described so far in various Vibrio species 75.

Flaws of tdh/trh as markers of virulence
Unfortunately, the use of tdh and trh as pathogen screening markers had major flaws. KP was
only effective in identifying strains harboring tdh, and some clinical isolates did not contain either
of tdh or trh

8,19,91,92

. Also, deletion of these markers does not ameliorate disease in an animal
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model, and environmentally, a high proportion of tdh and/or trh does not correlate with an increase
of outbreaks 20,72,87,93. This is partly due to the fact that many other species of marine bacteria of
unknown virulence potential also harbor homologous genes

94–96

. This suggests that further

research is needed in identifying virulence factors important in V. parahaemolyticus pathogenicity
in humans 20,81,97,98.

Urease
V. parahaemolyticus does not typically produce urease, but some V. parahaemolyticus strains
carry a ure cluster that enables the production of the enzyme 85,99. Urease is an enzyme that breaks
down urea into ammonium carbonate. It is produced by many bacteria, fungi, plants, and some
vertebrates

99

. Pathogenic bacteria such as certain strains of Staphylococcus spp., Helicobacter

spp., and Mycobacterium spp. typically encode urease

99

. Bacterial ureases are involved in the

formation of ammonia during the process of infection, which reduces the acidity of the local
environment, beneficial for bacterial survival

85,99

. Urease also contributes to damage of host

epithelial cells by activating host monocytes and neutrophils to secrete inflammatory cytokines
85,99

. Urease activity may aid in the colonization of host tissue by bacteria by inhibiting the

biosynthesis of mucus and cause intestinal mucus to disassemble at the mucosal surface, allowing
for better access of invading bacteria to the epithelial cells 100–103. Though urease is not essential
for V. parahaemolyticus infection, it is suggested that it contributes to increased survival of V.
parahaemolyticus and can be diagnostic for strains harboring Trh, though not those harboring Tdh
85,103

.
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Vibrio Pathogenicity Islands
Pathogenicity Islands – General
Pathogenicity Islands (PaIs) are a type of genomic island (GI) found on the chromosomes of
many bacteria

104

. PaIs are characteristically large chromosomal regions (10 to 200 kb) inserted

near tRNA genes and typically harbor functional mobility elements (i.e., direct repeats, integrases,
transposases, insertion sequences), and differ in base composition from the core genome.
Importantly, they contain virulence genes and are present in pathogens but absent in benign
relatives

55

. PaIs typically have a mosaic structure due to their numerous acquisitions and

adaptations

55

. Many bacterial pathogens, both gram-negative and gram-positive, have PaIs,

including prominent human pathogens such as V. cholerae, V. parahaemolyticus, Helicobacter
pylori, Escherichia coli, Salmonella spp., Shigella spp., Pseudomonas syringae, Listeria spp.,
Staphylococcus aureus, Streptococcus spp., Enterococcus faecalis and Clostridium difficile 104.

VPaI 1-7
The first fully sequenced V. parahaemolyticus genome was completed in 2003 from the
pandemic clonal complex strain

RIMD2210633

105

. V. parahaemolyticus contains two

chromosomes. The pandemic strain genome contained seven Vibrio Pathogenicity Islands (VPaIs),
with VPaI-1, -4, -5 and -6 exclusive to the pandemic strain

105,106

. This lineage of V.

parahaemolyticus gained its human pathogenicity from these VPaIs from unrelated lineages
34,65,98,105–109

. Espejo et al. (2017) reviewed the plausible origins for each VPaI and indicates that

the O3:K6 non-pathogenic founder strain acquired a toxRS and at least seven novel genomic
islands 110. All seven VPaIs contain the typical characteristics of pathogenicity islands as defined
above, such as large size (all were 10-81kb), flanked by direct repeats, G+C content lower than

9

the rest of the genome (except VPaI-2), and flanked by integrases or transposases for mobility.
VPaI-1-4 were inserted adjacent to tRNA genes 106.

VPaIs known to confer virulence
Despite the numerous VPaIs identified from the pandemic clones, almost all clinical V.
parahaemolyticus isolates contain either one or both hemolysins tdh and trh alongside a Type
Three Secretion System (T3SS) locus on one of three evolutionarily distinct but related VPaI:
VPaIα, VPaIß, and VPaIγ

75,98,105,106

. Until recently, researchers named each VPaI based on the

strain that harbored them. VPaIα (tdh+) was previously reported as Vp-PAIRIMD2210633 98/Vp-PAI
105
98

/VPaI-7

106

/tdhVPA

65

, whereas VPaIß (trh+) was previously reported as Vp-PAITH3996

/trhVPA 65,109. Xu et al. designed a non-strain specific naming system for these islands based on

the previously designated T3SS they harbored 107. The T3SS2 on VPaIα is evolutionarily divergent
from the T3SS2 on VPaIß/γ; thus these secretion systems are termed T3SS2α on VPaIα, and
T3SS2ß on VPaIß

98,107

. VPaIγ contains genetic elements from both VPaIα and VPaIß

107

, thus

due to this hybrid nature was termed “VPaIγ” 65,98,107,109 . A gene map of all three VPaI from Xu
et al. (2017) is shown in Figure 1.1 107.
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Figure 1.1: Comparison of gene content and conservation in a typical VPaIα, VPaIβ, and
VPaIγ. VPaIα was derived from ST3 strain RIMD2210633, VPaIß was derived from ST631 clade
II isolate MAVP-Q, and VPaIγ was derived from ST631 clade I isolate MAVP-R. ORFs are
depicted in defined colors, and similarities (≥75%) among ORFs are illustrated in gray blocks.
Figure from Xu et al. 107

VPaIα, first described in strain RIMD2210633 as VPaI-7, is currently the most extensively
studied VPaI as it is the VPaI harbored by the pandemic clonal complex of V. parahaemolyticus,
which causes the majority of infections by V. parahaemolyticus globally 105. VPaIα, as described
in strain RIMD2210633 (NC_004605 region between VPA1312 and VPA1395), is 81-kb [83 open
reading frames (ORFs)] and is located on chromosome 2 in RIMD2210633 110. Notably, it contains
two copies of tdh [tdh1 and tdh2 alleles (tdhS/A respectively)

65

]

75,78,111

, cytotoxic necrotizing

factor, an exoenzyme T gene, ﬁve transposase genes, and T3SS2α apparatus as well as several
T3SS secreted toxins 107.
VPaIß is evolutionarily divergent from VPaIα, with limited shared genetic content 65. VPaIß
from ST631 clade I strain MAVP-R (MF066647.2) is 96-kb and contains 88 ORFs 65,107 with ~78
ORFs unique to VPaIß 107 when compared to VPaIα from strain RIMD2210633. VPaIß is located
11

on either chromosome of V. parahaemolyticus dependent on strain 65. VPaIß contains a T3SS2ß,
which is related to the T3SS in non-O1, non-O139 strains of V. cholerae 98, and harbors one copy
of trh 98. The VPaIß (from strain MAVP-R) contains other interesting gene content including an
integrase, transposases, a urease gene cluster, and a peptide/nickel transportation system 65,98.
By 1990, isolates of V. parahaemolyticus harboring a VPaI that contained both tdh and trh
caused gastroenteritis 73. Bioinformatics analysis of quality assemblies identified that all strains
harboring tdh and trh concurrently, harbor these together in VPaIγ 107. VPaIγ is 102-113-kb (~105114 ORFs) and is located on chromosome 2 in sequenced genomes. Analysis of this island
indicated that the gene content is a hybrid of VPaIα and VPaIß 107. The 5’ end of the island contains
a mix of genes from both VPaIα and VPaIß, including a tdh gene homologous to that from VPaIα
107

. Interestingly, this tdh gene, though apparently from VPaIα, is flanked by gene content from

VPaIß 107. The core of the island is orthologous in content and syntenous with VPaIß, but 3’ end
of the island is highly conserved with that of VPaIα 97,107.

Secretion Systems and their Effectors
Secretion Systems
Bacteria have developed numerous mechanisms to increase their environmental fitness or
pathogenic success. The utilization of a protein secretion system is a method commonly used
among bacterial pathogens. Bacterial secretion systems are highly controlled and specific
machinery that transfer multiple bacterial encoded proteins across phospholipid membranes

112

.

As reviewed in Green and Mecsas (2016), bacterial pathogens often use these systems to
successfully invade hosts, damage host tissue, and evade host immune defenses 113.
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To date, there are seven bacterial secretion systems. The first six secretion systems are in
gram-negative bacteria and the seventh is found in only a few species of Mycobacteria and
Corynebacteria. The six gram-negative secretion systems are depicted in Figure 1.2 as originally
published by Gunasinghe (2017)

114

. Type I Secretion Systems (T1SS) resemble ATP-binding

cassette (ABC) transporters, and they transport their substrates across both inner and outer
bacterial membranes 113,115. Type II Secretion Systems (T2SS) form a channel in the outer bacterial
membrane, and transport folded proteins from the periplasm of bacteria, across the outer
membrane, into the extracellular environment 113. Type III Secretion Systems (T3SS) are discussed
below. Type IV Secretion Systems (T4SS) are related to bacterial DNA conjugation systems. They
can transport single proteins, protein-protein, and DNA-protein complexes across both its own
bacterial inner and outer membranes, but also other bacterial and eukaryotic membranes allowing
for direct injection of the substrate into a recipient cell’s cytosol 113,116. Type V Secretion Systems
(T5SS) are unique systems of autotransporters that allow secretion of proteins or groups of proteins
across the outer membrane of gram-negative bacteria

113,117

. Type VI Secretion Systems (T6SS)

are large structures that, like T3SSs and T4SSs, translocate proteins directly from their cytosol into
the cytosol of other cells in a contact-dependent manner, though T6SS can translocate proteins into
both bacterial and eukaryotic cells

113,118

. Type VII Secretion Systems (T7SS) are the secretion

systems specialized for transport of proteins across the heavily lipidated cell wall layer found in
gram-positive organisms such as Mycobacteria and Corynebacteria 113.
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Figure 1.2. Architecture of the major protein secretion systems found in gram-negative
bacteria. Figure from Gunasinghe (2017) 114. Of the six major gram-negative protein secretion
systems, ﬁve span the inner and outer membranes and the periplasm. These nanomachines are
thereby trapped in the peptidoglycan layer. The T1SS, T3SS, T4SS, and T6SS collect substrate
proteins directly from the cytoplasm for secretion across both membranes, while the T2SS collects
substrate proteins from the periplasm with their delivery there being via the Sec translocon (shown)
or Tat transport system (not shown).

T3SS
Discovered in the 1990s

119

, the T3SS is a bacterial needle-like apparatus that can detect

eukaryotic cells, and inject bacterial protein effectors directly into the plasma membrane and
cytoplasm of the eukaryotic cell 1,20,120. Once in the eukaryotic cell, these bacterial effectors can
hijack host cell signaling and can manipulate host cell functions to benefit the bacteria

20,119,120

.

This apparatus, termed the injectisome, is evolutionary related to the components of the bacterial
flagellum that are involved in flagellar structure assembly 1,119,121.
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Though also essential to some symbionts, T3SSs are typically found in gram-negative
animal, plant, insect and amoeba pathogens, and tend to contribute to their virulence

119

. Some

important human pathogens that use T3SSs for their virulence include Salmonella enterica
serovars, Shigella spp., Yersinia spp., Chlamydia spp., Pseudomonas spp., Vibrio spp., Bordetella
spp., and pathogenic strains of E. coli 112,119.
A total of 20-30 proteins make up the structure of the injectisome, forming three primary
sections: the secretion apparatus, transposon pore, and needle
traverses both the inner and outer bacterial membranes

1,20

1,20

. The secretion apparatus

. The transposon pore is composed of

secreted proteins called translocators, which form a hole crossing the target eukaryotic membrane
1,20

. The approximately 60-nm-long needle is polymerized and extended into extracellular space

to connect the secretion apparatus and transposon pore

1,20,119

. Genes for the injectisome and its

translocators are commonly encoded within a single gene cluster located on a mobile genetic
element such as a plasmid or pathogenicity island and thus can spread between bacteria through
the process of HGT 119.

T3SS Effectors
T3SSs typically deliver multiple effector proteins in a coordinated fashion to modulate a variety
of complex cellular processes enabling the bacterium to colonize its host

20,112

. T3SS effectors

typically function through some of the following themes: mimicry of host cell proteins, covalent
modifications of host cell proteins (e.g. phosphorylation, acetylation, and AMPylation) to
transiently alter the activity of the host cellular targets, work in concert with other effector proteins,
and work under precise temporal regulation/localization

112

. T3SS effectors have functional

redundancy in that they may have different biochemical activity, but target a similar cellular
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process for a similar net result

112

. Homologous effectors can be encoded by very dissimilar

pathogens, but each homolog may produce a different effect in their recipient hosts

112

.

Importantly, T3SS effectors are often encoded outside of the genetic block encoding the
injectisome apparatus, allowing for greater nucleotide variation and recombination among
effectors while retaining a functional secretion apparatus 119.

V. parahaemolyticus T3SSs and Virulence Effectors
V. parahaemolyticus T3SS
All V. parahaemolyticus have an ancestral T3SS (T3SS1). Some pathogenic V.
parahaemolyticus also have a second horizontally acquired T3SS harbored on VPaIα/ß/γ (T3SS2α
or T3SS2ß), which makes them enterotoxic 9,84,98,105,119,122. T3SS1 is located on Chromosome 1 in
all V. parahaemolyticus 35. T3SS1 effectors have a cytotoxic effect in cell culture, but they are not
an important component of enterotoxicity 8,9,123,124. T3SS1 has four main effectors, VopQ, VopS,
VopR, and VPA0450 (Table 1.1, adapted from Wang et al. 2015) 6 that initiate a series of events
in tissue culture that cause autophagy, membrane blebbing, cell rounding, and cell lysis

1,123

.

T3SS1 effectors are thought to be important for systemic V. parahaemolyticus infections and may
determine the final outcome of disease 125.
T3SS2 is an accessory system on VPaIα/ß/γ, primarily in pathogenic strains of V.
parahaemolyticus 1,23,35,70,105,122. The T3SS2 found in V. parahaemolyticus has close homology to
the T3SS Hrp1 system in Pseudomonas syringae 1. Effectors of T3SS2α have been extensively
studied and are discussed in the following section. Some of the effectors with no proven role in
human disease are also secreted by T3SS2ß, but there is little homology between the primary
T3SS2α effectors VopV and VopZ with those similar regions found on VPaIß/γ
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107

. During

gastrointestinal infections, the effectors from both T3SS2α/ß impair epithelial cell function and
structure resulting in damage to the intestinal lining, inﬂammation, and diarrhea 9.

T3SS2 effectors and Gastroenteritis Pathogenesis
The human gut mucosa makes up the primary barrier to the underlying tissues and organs
of the human body. The first layer of the gut mucosa are epithelial cells termed enterocytes, with
occasional specialized epithelial cells. One mechanism of gut pathogen proliferation and survival
is to disrupt this barrier to gain access to the tissues underneath 126.
After consumption, when V. parahaemolyticus makes it to the intestinal tract, it first must
attach to the enterocytes. A tight attachment to enterocytes is necessary for the bacterial T3SS
needle to form a channel and pump effectors into the host cell. Throughout the length of the
gastrointestinal tract, there is variation in mucus density, commensal ﬂora composition and a wide
diversity of cell types 20. Due to the highly dynamic environment of the gastrointestinal tract, V.
parahaemolyticus has developed multiple adhesion mechanisms to allow for efﬁcient attachment
to host cells throughout the intestine

20,125

. This attachment is modulated by the adhesion

molecules: Mannose Sensitive Hemagglutinin (MSHA) Type IV Pilus and Multivalent Adhesion
Molecule 7 (MAM7), which bind to the ﬁbronectin and phosphatidic acid on the enterocyte
129

6,20,127–

. Though more studies are needed, it is also suggested that Cell-Associated Hemagglutinin

(cHA), GlcNAc Binding Protein A (GbpA), and Capsular Polysaccharide (CPS) also have an effect
on adhesion to enterocytes 20,125,130–133.
After attachment, the T3SS2’s translocators form a pore in the enterocyte membrane
allowing the T3SS to begin pumping virulence effectors into the enterocyte. The T3SS
translocation pores forms preferentially in lipid raft microdomains that are rich in cholesterol and
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glycosphingolipids in the enterocyte membrane. The cholesterol in these lipid rafts binds the TTSS
translocator proteins so they can assemble as pore 134. After assembly of the translocon pore, the
T3SS can pump virulence effectors into the enterocyte.
Characteristic pathological changes during V. parahaemolyticus infection include
disruption of the intestinal epithelium, modulation of epithelial cell signaling, epithelial cell death,
and intense inflammation. These pathological changes are primarily attributed to V.
parahaemolyticus TTSS2 effectors 20. V. parahaemolyticus’s T3SS2 and its effectors have been
extensively characterized in VPaIα (Table 1.1) 6. The eight characterized VPaIα effectors include
VopA/P, VopC, VopL, VopO, VopT, VopV, VopZ, and VPA1380. VopV and VopZ are the two
primary effectors necessary for successful V. parahaemolyticus infection. VopA, VopC, and VopT
directly alter the activity of eukaryotic cell signaling proteins by post-translation modification 125.

V. parahaemolyticus Gastroenteritis Pathogenesis - Epithelial disruption (VopV, VopL,
VopC, VopO)
One of the common pathologies of bacterial gastric infections includes disruption of the
intestinal epithelium

135

. One function of the gastrointestinal epithelium is to form a selectively

permeable barrier. This barrier controls the passage of nutrients, water, and ions into the tissue
below

20,136

. By disrupting this primary barrier, gastric pathogens can increase non-selective

intestinal permeability, modulate ion and ﬂuid efﬂux and allow bacteria access to deeper tissues
and interfere with host immune responses 20. This access to deeper tissues is often associated with
severe clinical symptoms 126. During infection, V. parahaemolyticus induces significant epithelial
damage (Figure 1.3), including epithelial cell detachment and disruption of the villus structure,
triggering a substantial inflammatory response that contrasts with V. cholerae which does not
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cause inflammatory gastroenteritis

125,135,137

. This epithelial damage occurs both on the large scale

of villus architecture, but also the small scale of effacement and elongation of microvilli 135,138,139.
V. parahaemolyticus colonizes throughout the small intestine (duodenal) and large intestine
(rectal) tissues and is highest in the distal small intestine 125. During infection, V. parahaemolyticus
exhibits a distinct colonization pattern of discrete microcolonies rather than even distribution
across the entire epithelial surface 138.

Figure 1.3. Schematic of the kinetics of V. parahaemolyticus-induced damage to the intestinal
epithelial surface. The purple rods represent V. parahaemolyticus. Figure from Ritchie et al. 2012
138
. Following initial attachment, V. parahaemolyticus induces erosion of microvilli and depletion
of cytoplasmic contents resulting in the formation of bacterial clusters located just below the level
of the surrounding epithelium. Continued depletion of epithelial cell contents either by cytoplasmic
‘blebbing,’ whole-cell extrusion and microvilli elongation around the edge of the cluster, leaves
V. parahaemolyticus clusters situated within deeper cavities in the epithelium. Eventually, this
leads to the disintegration of normal villus structure and the generation of large amounts of luminal
debris. These pathological changes appear to be attributed to T3SS2 as a similar pathology was
observed in rabbits infected with mutants lacking TDH or T3SS1.
The nucleation of actin, actin-bundling, and formation of stress fibers/filopodia/actin
ruffles serve both a structural and signaling purpose of the host cells. When pathogens disrupt the
normal branched architecture of the actin cytoskeleton structure of host epithelial cells, these cells
lose their shape and tight junctions to surrounding cells, which facilitates bacterial dissemination
140

. The proper response to infection and damage cannot be induced when the normal cellular

signaling network is disrupted

140

. During V. parahaemolyticus infection, epithelial disruption is

primarily caused by the T3SS effectors VopV, VopL/F, VopC, and VopO which target the actin
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cytoskeleton 125,141,142. VopV binds and bundles the actin in host cells, VopL nucleates actin which
forms stress fibers thus altering host cell shape, VopC activates GTPases that lead to the formation
of stress fibers, actin ruffles and filipodia, and VopO induces stress fiber formation

125,141–145

.

Interference and reorganization of the actin cytoskeleton affects not only cell structure, but it also
activates several signal-transduction pathways, including two important for bacterial infection: the
mitogen-activated protein kinases (MAPK) signaling and NF-kB inflammatory responses 141,146
Once secreted into enterocytes, via its F-actin binding-domains, VopV binds to actin filaments
and the actin-cross linking protein filamin

139

. Then by bundling the actin, VopV induces the

rearrangement of the apical epithelial cell membrane, eliminates the actin-filled microvilli brush
border, and elongates a few microvilli

141

. This effacement of the brush border enhances V.

parahaemolyticus adhesion to the enterocyte 139. It is proposed that the effacement either provides
an altered surface for adhesion or exposes membrane domains and/or a speciﬁc host receptor that
V. parahaemolyticus does not have access to with an intact brush border

139

. It is currently not

known how the F-actin-binding activity of VopV affects VopV-dependent inflammation and
enterotoxicity 141. VopV is considered the primary effector in VPaIα and is responsible for T3SS2dependent enterotoxicity, and colonization

139,141

. In the rabbit ileal loop model, vopV deletion

mutant V. parahaemolyticus induces intestinal damage similar to that of no secretion of any T3SS2
effector and non-infected control, compared to the severe intestinal inﬂammation (epithelial loss,
edema, neutrophil inﬁltration in the lamina propria and submucosal area, loss of goblet cells, and
bleeding) seen with VopV secretion 141. This suggests that the effacement of the enterocyte brush
border is a critical step for V. parahaemolyticus infection 139,141.
VopL, VopC, and VopO also affect the actin cytoskeleton, but these effectors are not required
for enterotoxicity

141–144,147

. The protein domains of VopL mimic a eukaryotic actin-nucleating
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protein that allows it to remodel the actin network by inducing the formation of unbranched actin
structures rather than the branched networks

142

. This actin nucleation process forms elongated

stress fibers and alters the cell shape 1,142,148. VopC utilizes a mechanism other than direct contact
to manipulate the actin cytoskeleton 143,144. VopC activates the small GTPases Rac and CDC42 to
contribute to stress fibers, actin ruffles, and filipodia formation

143,144,149

. Zhang et al., Okada et

al., and de Souza Santos et al. suggest that VopC and VopL help facilitate the entry of V.
parahaemolyticus into non-phagocytic host cells 143,144,150. Recently, a germ-free mouse model was
developed to assess gastrointestinal pathogenesis of V. parahaemolyticus 151. This model enabled
assessment of gastrointestinal pathogenesis in earlier hours of infection to evaluate initial tissue
invasion rather than the final result of maximal tissue damage at the end of infection as seen in
previous models

138,144,151

. In this model during the early hours of infection VopC promoted

epithelial cell invasion and increased gastrointestinal pathogenesis 151. VopO is an effector that has
been shown to activate the RhoA-ROCK signaling pathway, which induces actin stress fiber
formation, contributing to the disruption of the host epithelium 145.

V. parahaemolyticus Gastroenteritis Pathogenesis – Cell Death (VopT)
Another characteristic pathological change during V. parahaemolyticus infection includes
epithelial cell death. During infection, cell death can be a host defense mechanism, to limit
infection and colonization by enteric pathogens 126,152. Some enteric pathogens block apoptosis to
preserve their replication sites, while others such as V. parahaemolyticus, trigger cell death to
induce breaches in the epithelium to gain access to underlying tissue 126,152.
VopT shares the ADP-ribosyltransferase domain of Pseudomonas aeruginosa cytotoxins ExoT
and ExoS, with biological activity more similar to that of ExoS 124. VopT is cytotoxic to cultured
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intestinal cells but is not enterotoxic 124,141. VopT can modify Ras, which could affect any number
of the Ras signaling pathways such as the mitogen-activated protein kinases (MAPK) and
phosphoinositide-3 kinase (PI3K) pathways, which are important in controlling several functions,
such as cell growth and survival 124,153,154.

V. parahaemolyticus Gastroenteritis Pathogenesis – Inflammation (VopZ, VopA/P)
Finally, another hallmark of V. parahaemolyticus induced gastroenteritis is severe
inflammation, which is specifically induced by V. parahaemolyticus, not the host in response to
the extensive tissue disruption 125. Pathogens trigger inflammation as a mechanism to outcompete
the commensal microbiota, disrupt tight junctions and impair gut barrier integrity 126,155,156. Some
pathogens exhibit higher resistance to host mucosal antimicrobial peptides compared to
commensals; thus inflammation alters the microbiota composition in favor of the pathogen 126,157–
159

. Certain pro-inflammatory cytokines produced by host cells, such as Tumor Necrosis Factor-α

(TNF-α), disrupt the tight junctions between the enterocytes lining the intestinal tract
This disruption allows bacteria access to deeper tissues

126,155,156

126,155,156

.

. V. parahaemolyticus induces

inflammation through recruitment of inflammatory cells, such as PMNs, and induces host cell
transcription of the pro-inflammatory cytokines TNF-α, Interleukin-1β (IL-1β), Interleukin-6 (IL6), and Interleukin-8 (IL-8) 125,135.
Commonly, the effectors of bacterial pathogens target the host intracellular signal
transduction cascades

160

. Two of the most frequent effector targets are the inflammatory cell-

survival pathways controlled by the MAPK signaling cascade, and the NF-kB signal transduction
pathway 160. The MAPK signaling cascade is essential for normal operation of the eukaryotic cell
such as cellular metabolism, growth, and division, as well as inducing inﬂammation as an
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antimicrobial defense mechanism

160

. The NF-kB signal transduction pathway is an important

component of innate immunity, with a role in apoptosis, cell survival, and cytokine production
160,161

. Inhibition of these pathways leads to inflammation, distorted epithelial structure, cell death,

reduced barrier function, and recruitment of PMNs 147.
The second critical V. parahaemolyticus T3SS2 effector is VopZ. VopZ is a
multifunctional effector that is essential for V. parahaemolyticus colonization, enterotoxicity, and
induction of diarrhea 147. VopZ inhibits activation of the kinase TAK1, which is important for the
activation of the two signaling pathways MAPK and NF-κB 147,162. Previous studies have shown
that absence of TAK1, and thus non-activation of MAPK and NF-κB signaling pathways, in the
intestinal epithelium can lead to phenotypes such as inflammation, apoptosis, distorted epithelial
structure, mislocalization of tight junction proteins, and reduced barrier function 125,147,163. These
phenotypes are advantageous for invading enteric pathogens, allowing for increased colonization
and access to deeper tissues 141,146.
Another inflammation-inducing effector is VopA (also referred to as VopP). VopA
acetylates MAPK kinases, preventing phosphorylation of the kinase, thus inhibiting the MAPK
signaling pathways

1,164,165

. Despite its role in controlling cytokine production, VopA is not a

critical effector for infection as there was no obvious reduction in enterotoxicity in rabbit ileal loop
141

.
VPA1380 is a T3SS secreted cysteine protease that likely targets a host substrate

166

. Its

role in V. parahaemolyticus infection is not known. When expressed intercellularly VPA1380 is
toxic to yeast, but it is not enterotoxic in the rabbit ileal loop model 141,166.
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Table 1.1: Known V. parahaemolyticus virulence effectors and their biological activity.
Gene names are orthologs found in strain RIMD2210633 VPaIα (NC_004605 region between
VPA1312 and VPA1395). “+” = the presence of effector on VPaIα/ß/γ. “-” = the absence of
effector and predicted effector on VPaIα/ß/γ. “~” = divergence between orthologs found in
VPaIß/γ compared to the characterized effector in VPaIα.
Effector

Gene

Biological Activity

Effects on host cells

Gene presence
on VPaI
α
ß
γ

Toxins
Tdh

tdh

Forms pores on cells

Cytotoxicity and enterotoxicity

+

-

+

Trh

trh

Forms pores on cells

Cytotoxicity and enterotoxicity

-

+

+

Tlh

tlh

Hemolysin activity

Cytotoxicity

N/A

N/A

N/A

Forms pores and binds VATPase
Inhibition of Rho by
AMPlyation
Phosphatidylinositol
phosphatase
Binds PIP2 in membrane

Autophagy, cell lysis, MAPK
activation, IL-8 secretion
Cell rounding, phagocytes
invasion
Membrane blebbing,
destabilization
Promoting refolding of T3SS
effectors

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Blocking of phosphorylation
and ATP binding
Cytotoxicity and yeast growth
inhibition
Stress fiber formation and cell
shape changing
Invasion of non-phagocytic
cells, enterotoxicity
Induces stress fiber formation

+

+

+

+

-

-

+

+

+

+

+

+

+

-

-

Enterotoxicity and blunting of
villi
Enterotoxicity and
colonization

+

~

~

+

~

~

Toxicity in yeast

+

-

-

T3SS1 effectors
VopQ

VPA1680

VopS

VPA1686

VPA0450

VPA0450

VopR

VPA1683

T3SS2 effectors
VopA/P

VPA1346

VopT

VPA1327

Inhibition of MAPK by
acetylation of MKK
Ras ADP-ribosylation

VopL

VPA1370

Actin nucleation

VopC

VPA1321

VopO

VPA1329

VopV

VPA1357

Activation of Rac and
CDC42 by deamination
Activates the RhoA-ROCK
pathway
Actin binding and bundling

VopZ

VPA1336

VPA1380

VPA1380

Inhibition of TAK1 and
downstream MAPK and NFkB
Cysteine catalysis dependent
on IP6
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Epidemiology of V. parahaemolyticus
V. parahaemolyticus discovery
V. parahaemolyticus was discovered by Tsunesaburo Fujino of the Research Institute of
Microbial Diseases (RIMD), Osaka University in 1950 in Osaka, Japan after an outbreak of acute
gastroenteritis from Shirasu in 272 individuals, 20 of whom died 167. In the decades after this event,
outbreaks continued and V. parahaemolyticus became recognized as the leading cause of seafoodborne gastroenteritis 168–175.

ST3 (O3:K6)
Prior to 1995, gastroenteritis caused by sporadic V. parahaemolyticus infection was
associated with many serotypes 45,176,177. In 1995, an outbreak of V. parahaemolyticus occurred in
Calcutta (now known as Kolkata), India 2,26,176. This outbreak was caused by a novel strain of V.
parahaemolyticus with serovar O3:K6 (with numerous serovariants), later determined by Multilocus sequence typing (MLST) to be ST3 26,65,178,179. This ST3 strain spread throughout Asia180 178,
Africa181, Europe182, and North and South America

18,173,178,180,183,184

and so was called the

pandemic clonal complex of strains 26,110,178. Since then, ST3 strains have caused numerous foodborne outbreaks in Asian countries, the United States and worldwide

1,110

. ST3 strains of V.

parahaemolyticus have only caused two outbreaks in the United States, one from Texas oysters
and the other from New York oysters in 1998 26,45,46. Although not prevalent in the United States,
the pandemic complex of ST3 strains causes the most disease globally

26,45,173,176,178,185–188

. The

T3SS effectors on the VPaIα harbored by the pandemic strain induced the gastroenteritis seen in
these outbreaks 65,98,105,106.
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Arrival in the United States
The first reported V. parahaemolyticus outbreak in the United States was in Maryland in 1971,
with three outbreaks 189. The illnesses were linked to steamed crabs 189. There was variation in the
clinical isolates from these outbreaks with multiple serotypes, and both KP+ (VPaIα) and KPisolates (no island/VPaIß/VPaIγ)

189

. V. parahaemolyticus has continued to cause sporadic

infections in the United States 18. Serotypes with O4 were the most dominant in the United States
45,176,177

. In the United States, the most clinically prevalent STs harbor VPaIß and VPaIγ 19,39,40,190.

Northeast United States
Historically there was low disease incidence of V. parahaemolyticus infections in the Northeast
United States. This low prevalence of disease in the Northwest Atlantic was attributed to cooler
water and unfavorable conditions for pathogen populations to establish compared to warmer
southern regions like in the Gulf of Mexico 33,52. The rare outbreaks that did occur were driven by
anomalously warm ocean temperatures, and introduced strains 22,48,50,185. The recent increase in V.
parahaemolyticus infections in the North Atlantic are attributed to the invasion and establishment
of Pacific-native lineages, in particular hypervirulent ST36, as well as a trend of warmer than usual
ocean temperatures allowing more successful movement and establishment of Gulf of Mexico
(GOM) native V. parahaemolyticus populations

22,26,35,48,191–196

. During this time VPaIs were

donated from the invading lineages to the native New England populations 11,22,197.
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Figure 1.4. Clinically prevalent Sequence Types (ST) and corresponding pathogenicity island
content. Adapted from Xu et al. 2017 11. A) The total number of clinical and environmental
isolates from prevalent V. parahaemolyticus lineages reported in four Northeast US States (ME,
NH, MA, and CT) from 2010-2016. B) Percentage of pathogenicity island type from prevalent V.
parahaemolyticus lineages reported in panel A. C) Distribution of VPaI type of all gastric
infections reported in ME, NH, MA, and CT.

ST36 (O4:K12) and other Pacific lineages
V. parahaemolyticus ST36 is a long-time resident lineage originating from the Pacific
Northwest and is the most clinically prevalent lineage of V. parahaemolyticus in the United States
and Canada 22,39,40,48,107,177,193,198. ST36 was first identified in the Pacific Northwest (PNW) in 1979,
and until 2006, this PNW resident lineage only contributed to infection on the Northwest US coast
52,177,180,199
200

. In 1997, ST36 caused the first outbreak linked to US product along the Pacific Coast

. Infections from this outbreak caused 207 confirmed cases and one death 200. The outbreak was

precipitated by unusually warm ocean temperatures

200

. ST36 was also a major contributor to

multiple outbreaks in 2006 in New York, Oregon, and Washington 201. Prior to 2012 members of
the ST36 clonal complex were introduced into the Atlantic Ocean by an unknown route and
established robust local populations 22,48. In 2012 members of these populations caused a series of
outbreaks from Atlantic shellﬁsh originating from New York and Spain 48,49.
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Paciﬁc-derived ST36 lineage continues to dominate infections in the Northwest Atlantic 107.
This pattern of invasion of Pacific-native strains into the Atlantic causing outbreaks also included
pathogenic sequence types ST636 and ST43 39,40. In 2011 and 2013 and in continuing years ST636
and ST43, respectively, caused infections linked to products from along the Northeast US coast 22.
ST36, ST43, and ST636 all harbor VPaIγ.

ST631
In the past decade, a new lineage of pathogenic V. parahaemolyticus emerged in the
Northwest Atlantic known as ST631. ST631 was first reported in 2007 from a clinical case reported
in Maryland that was traced to oysters harvested in Florida 198. The second reported clinical case
arose two years later traced to Prince Edward Island, Canada 40. Since then, ST631 infections have
increased with 35 conﬁrmed cases reported between 2010 and 2015 in just four Atlantic coastal
US states

197

. With this increase, ST631 has become the second most predominant pathogenic

lineage in the Northwest Atlantic, after ST36

22,40,197,198

. This emergence of ST631 as a major

endemic pathogen 107 also coincided with a trend in warmer ocean temperatures in the Northwest
Atlantic and invasion by nonresident pathogen lineages

22,48,50,185

. Non-native pathogen lineages

included several Paciﬁc native lineages (ST36, ST43, and ST636), and long-time residents of the
Gulf of Mexico (ST34, ST110, and ST308).
Population analysis of the Northwest Atlantic clinical and environmental isolates indicates
that two clades diverged from a common ST631 ancestor, each with strains independently
acquiring VPaIs from the invading nonresident pathogen lineages 11,107. Isolates of ST631 clade I
harbored either no VPaI or VPaI-ß and were not clinically prevalent

107

. Analysis of the ST631

clade II isolates indicate that it is the clonal clade II that is the major Atlantic endemic pathogenic
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lineage

11

that dominates Atlantic-derived ST631 infections. ST631 clade II harbors VPaIγ that

was likely donated by the same population as ST36 during its Atlantic invasion 11,107.

Long-time residents of the Gulf of Mexico and their spread
The long-term resident lineages of the Gulf of Mexico (GOM) harbor primarily no island,
VPaIß, or VPaIγ. Strains harboring VPaIα are isolated occasionally, but have not established a
population since most tdh+ isolates in the area are also trh+ 53. STs such as ST34, ST110, and ST308
are native to the GOM that harbor VPaIγ have moved up the coast and are now resident in the
Northwest Atlantic 22,53,60,190,192.
GOM native ST34 was first reported in both the GOM and Massachusetts in 1998 107. During
the past decade, coinciding with a trend in warmer ocean temperatures, ST34, along with other
members of the Gulf of Mexico V. parahaemolyticus population 53,60,192, has continued its spread
north and in 2012 it was also recovered in New Hampshire, where it established residency 22. GOM
strains moving north have also spread their VPaIs via HGT to local populations 11. Analysis of the
VPaIs, show that during its spread north, ST34 donated its VPaIγ to the local North Atlantic
resident ST674, transforming it into a pathogen

11

. ST34 and ST674 are the most frequently

recovered pathogen lineages among environmental isolates, but despite harboring a VPaIγ, they
cause very few infections 107.

Flavors of VPaIγ
Pathogenic lineages of V. parahaemolyticus harboring VPaIγ are increasingly associated
with disease in North America

19,22,39,40,52,198

. Whereas most Northeast Atlantic V.

parahaemolyticus pathogens harbor related VPaIγ, there is variation in their clinical prevalence 11.
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A recent study by Xu et al. indicated that the geographical location and clinical prevalence of
VPaIγ could align with allelic variation and lineage of the tdh gene 11. There are currently seven
tdh alleles harbored by VPaIs. tdh1, tdh2, and tdh4 alleles are located on VPaIα, whereas VPaIγ
contains one of four distinct tdh alleles: tdh3, tdh5, tdh6, or tdh7 11.
In the United States, the primary populations of VPaIγ-harboring V. parahaemolyticus are
either in the Pacific Ocean, the Gulf of Mexico, or the Atlantic Ocean. tdh3 is exclusively harbored
in Pacific-derived lineages, and V. parahaemolyticus harboring tdh3-VPaIγ are linked to high
clinical prevalence 11. tdh5 is closely related to tdh3, but is in V. parahaemolyticus lineages from
the Gulf of Mexico and the Atlantic Ocean 11,22,107,190,198. All lineages harboring tdh5-VPaIγ are of
low clinical prevalence 11. tdh7 is divergent from the other tdh alleles, and has been isolated in
both Pacific-derived and Gulf of Mexico-derived lineages 11,39,40,53. tdh6 has been found in lineages
worldwide

11

. V. parahaemolyticus harboring all of these VPaIγ lineages have invaded the US

Atlantic coast, causing infections, and are spreading the VPaIs to the local V. parahaemolyticus
residents, transforming them into pathogens 11. Since pathogen lineages harboring tdh3/tdh5/tdh6VPaIγ vary so much in clinical and environmental prevalence, this suggests that each VPaIγ could
have evolved to confer different degrees of virulence 11.
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RESEARCH OBJECTIVES
Chapter II: What T3SS effectors does VPaIγ encode?
V. parahaemolyticus strains harboring VPaIγ cause the majority of infections in the North Atlantic,
yet the effectors on this island remain unidentified and uncharacterized. The first objective
(Objective I) is to identify the T3SS effectors that are present on VPaIγ. The approach to address
this objective was to conduct a bioinformatic prediction of putative effectors VPaIγ based on
nucleotide sequence similarity and protein domains to know T3SS effectors. The toxicity of the
predicted proteins in two eukaryotic models, as a proxy for enterotoxicity, was used to characterize
which toxins are likely most important to human disease.

Chapter III: Which VPaIγ T3SS effector alleles are important for human disease and
environmental prevalence?
There are four flavors of VPaIγ in the North Atlantic, reflected in the allelic variation of tdh on the
island. Each lineage varies in clinical and environmental prevalence, with tdh3-VPaIγ
predominantly causing infections yet rarely isolated environmentally, and tdh5-VPaIγ with the
reciprocal relationship. The second objective (Objective II) is to compare the T3SS effectors of
the local VPaIγ lineages to examine if sequence variation equates with differences in toxicity in
eukaryotic models of clinical and environmental fitness.
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Abstract
Vibrio parahaemolyticus, the leading cause of seafood-borne bacterial infections, recently
increased in clinical prevalence in the United States, particularly from sources in the northwest
Atlantic Ocean. Most pathogenic variants of V. parahaemolyticus harbor a mobile Vibrio
Pathogenicity Island (VPaI) encoding a diagnostic hemolysin gene (tdh and/or trh) and a Type III
Secretion System (T3SS). Three island types have been characterized and include VPaIα (tdh+),
VPaIβ (trh+), and a mosaic VPaIγ (tdh+/trh+). Although most infections globally are caused by
strains harboring VPaIα, for which several major effectors are known, infections in the United
States are predominantly caused by strains harboring VPaIγ, which is relatively uncharacterized.
Our goal was to identify effectors in VPaIγ using bioinformatics and bioassays. Analysis predicted
five putative effectors shared between VPaIβ and VPaIγ but absent in VPaIα. When expressed
intracellularly, three predicted effectors impaired Saccharomyces cerevisiae growth similarly to
the known effector VopA, suggesting they are T3SS2 effectors. However, a third predicted effector
did not impair growth, nor did VopZ, one of the major virulence determinants of VPaIα. Four
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effectors were cytotoxic to cultured human colon cells, warranting further investigation of their
role in human gastroenteritis.

Introduction
Vibrio parahaemolyticus is the leading cause of bacterial-induced seafood poisoning both
in the United States and worldwide. Infection with V. parahaemolyticus can take on three forms:
gastroenteritis, wound infections, and, rarely, lethal septicemia, with the most common form as
gastroenteritis

18

. Recent increases in infections in the Northeast US from Atlantic-harvested

shellfish coincided with warmer than usual ocean temperatures, and the invasion of a lineage of
the “hypervirulent” Pacific Northwest endemic pathogenic strain called Sequence Type (ST) 36
8,22,48,49

. Increasing illnesses have also been caused by an endemic pathogenic lineage, ST631 clade

II, first reported in the North Atlantic in 2007 and which acquired a VPaIγ from the ST36containing population

11,107

. Currently, ST36 causes the vast majority of infections in the North

Atlantic, followed by ST631 clade II 11,107.
The Type Three Secretion System (T3SS) is a needle-like apparatus that can inject effector
proteins directly through the plasma membrane and into the cytoplasm of a eukaryotic cell 20,120.
These effectors then can hijack host cell signaling and manipulate host cell functions to benefit the
bacteria

20,119,120

. V. parahaemolyticus has one ancestral T3SS on chromosome I that is not

important for human disease, and some strains, predominantly clinical isolates, have a second
accessory T3SS encoded by one of three related Vibrio Pathogenicity Islands (VPaI): VPaIα,
VPaIß, and VPaIγ 107. VPaIγ is a hybrid of genetic elements from both VPaIα and VPaIß 107, with
the core content orthologous and syntenous with VPaIß 97,107. VPaIß and VPaIγ are divergent from
VPaIα 107.
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Worldwide, V. parahaemolyticus strains harboring the VPaIα, known as VPaI-7
pandemic strain RIMD2210633

105

106

in

, dominate infections. VPaIα is the most extensively studied

VPaI with eight different T3SS effectors known and characterized: VopA/P, VopC, VopL, VopO,
VopT, VopV, VopZ, and VPA1380 139,141,147,162. Previous work had only established that VopV
and VopZ were critical for enteric disease in an infant rabbit model 139,141,147,162, however, a recent
study in germ-free mice has demonstrated that VopC not only promotes epithelial cell invasion
during early stages of infection but also contributes to gastrointestinal pathogenesis 151.
Strains harboring VPaIα rarely cause infections in the northeast United States. Instead,
strains harboring VPaIγ, or occasionally VPaIß, are isolated from the majority of clinical cases
(Figure 1.4) 11. Though VPaIß and VPaIγ encode a recognizable VopC homolog, the VopV and
VopZ effectors encoded in VPaIß and VPaIγ are highly divergent from those characterized in
VPaIα and in the case of VopV even lack key domains that promote actin remodeling

11

. This

suggests that unidentified effectors on VPaIß and VPaIγ could be primary virulence factors for V.
parahaemolyticus strains harboring these islands. The goal of this study is to identify T3SS2
effectors that are unique to VPaIγ that is associated with the clinically prevalent STs in the North
Atlantic.
T3SS effectors have a staggering level of diversity in structure with more than 75% of
characterized effectors having no detectable sequence similarity to other known T3SS effectors
202

. The lack of sequence similarity makes consensus on structural patterns among the effectors

challenging to parse out and difficult to predict. Despite this variation, computational analysis of
known T3SS effectors indicates a modular composition with multiple functionally distinct
domains or motifs

202,203

. Effectors typically have three distinct regions: the amino-terminal

secretion signal, followed by the optional chaperone-binding domain, and finally, the region that
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harbors host cell effector activities 202–207. In our study we utilized bioinformatic programs, some
of which specialize in T3SS effectors, to analyze open reading frames (ORFs) on VPaIα, VPaIß
and VPaIγ to predict

T3SS effectors, identify conserved domains, and calculate potential

orthologs. We then employed biological assays to evaluate the putative effectors effect on
eukaryotic cells to inform their potential significance during infection.

Results and Discussion
VPaIß and VPaIγ contain three putative effectors that are not present on VPaIα
To identify effectors on VPaIs we utilized the bioinformatic program pEffect, which
combines homology-based and de novo approaches to predict type III effector proteins

208

. This

program has a higher performance of identifying effectors over existing tools by identifying
effector patterns throughout the protein sequence rather than just the N-terminus allowing for
identifying a greater number and rapidly evolving effectors 208. To first evaluate the utility of this
tool we tested it against the well-characterized VPaIα from strain RIMD2210633 that contains
eight known effectors among its 83 ORFs, and in parallel analyzed representative VPaIß (from
strain MAVP-R, MF066647.2) containing 88 ORFs and VPaIγ (from strain MAVP-Q,
MF066646.1) containing 105 ORFs. The correct identification of known effectors from VPaIα
indicates this tool’s reliability to classify ORFs as virulence effectors correctly. This analysis
predicted three known effectors orthologous to VopA/P, VopC, and VopL, all previously
characterized in the VPaIα of strain RIMD2210633 in all three VPaI (Table 2.1, Figure 2.1). The
analysis also identified the known VPaIα effector VopO, 107. Similarly, it identified VPaIα effector
VopV and also predicted that the highly divergent ORFs encoded in the same location of VPaIγ
and VPaIß as effectors. However, pEffect failed to predict the known VPaIα effectors VopT
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(VPA1327) and VopZ (VPA1336). Finally, this analysis identified five putative T3SS effectors
among the ORFs in VPaIγ, all of which were also present in VPaIß but without identified homologs
in VPaIα 107.
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Table 2.1: Bioinformatic prediction of T3SS effectors.
Effector name

Locus ID

pEffect Prediction

Predicted Domains

BLASTx predicted
ortholog

CDD

SMART

Characterized effectors

VopA/P

VopC

VopL

VopO/ORF76

α: VPA1346

α:YES 69 PSIBLAST

ß: MAVPRPIeRC_00081

ß: YES 67 PSIBLAST

γ: MAVPQPI_00075

γ: YES 69 PSIBLAST

α: VPA1321

α: YES 70 SVM

ß: MAVPRPIeRC_00083
γ: MAVPQPI_00077

α: T3SS YopJ
family effector
VopA
ß: multidrug DMT
transporter permease

α: PRK15371,
Acetyltransf_14

α: --

ß: Acetyltransf_14

ß: LCR

γ: multidrug DMT
transporter permease
α: T3SS2 effector
GTPase-activating
deamidase VopC

γ: PRK15371,
Acetyltransf_14

γ: --

α: CNF1, CNF1-like

α: LCR

ß: YES 83 SVM

ß: Cytotoxin

ß: CNF1

ß: --

γ: YES 70 SVM

γ: Cytotoxin

γ: CNF1, CNF1-like

γ: --

α: Drf_FH1

α: WH2 (3), LCR (4)

ß: --

ß: WH2 (2), LCR (4)

γ: --

γ: WH2 (2), LCR (CT4291 3,
MAVP-Q 4)

α: --

α: --

ß: --

ß: --

γ: --

γ: --

α: VPA1370

α: YES 98 SVM

ß: MAVPRPIeRC_00080

ß: YES 93 SVM

γ: MAVPQPI_00074

γ: YES 98 SVM

α: VPA1329

α: YES 57 SVM

ß: MAVPRPIeRC_00082

ß: YES 65 SVM

γ: MAVPQPI_00076

γ: YES 68 SVM

α: Hypothetical
protein/T3SS2
effector VopL
nucleation of actin
polymerization
ß: Hypothetical
protein/putative type
III secretion system
effector protein Vop
hypothetical protein,
WH2 motif family
protein
α: Exoenzyme T
ß: hypothetical
protein/conjugal
transfer protein
TraA
γ: hypothetical
protein/conjugal

α: VPA1327

α: NO

α: VPA1357

α: YES 87 SVM

ß: MAVPRPIeRC_00066

ß: YES 72 SVM

γ: MAVPQPI_00061

γ: YES 87 SVM

α: VPA1336

α: NO

VopT

VopV

VopZ

VPA1380/ORF32

ß: MAVPRPIeRC_00049
γ: MAVPQPI_00044

ß: NO
γ: NO

α: VPA1380

α: YES 70 PSIBLAST

ß: MAVPRPIeRC_00039

ß: YES 69 PSIBLAST

γ: MAVPQPI_00032

γ: YES 70 PSIBLAST

ß: MAVPRPIeRC_00041

ß: YES 96 SVM

γ: MAVPQPI_00034

γ: YES 99 SVM

transfer protein
TraA
α: Conjugal transfer
protein TraA

α: ADPrib_exo_Tox

α: --

α: Hypothetical
protein

α: Glutenin_hmw,
PRK07764 (2)

α: Transmembrane region,
LCR (4)

ß: Hypothetical
protein

ß: --

ß: transmembrane region,
LCR (15)

γ: Treacle (2) PRK07764

γ: transmembrane region,
LCR (22)

α: --

α: LCR

ß: --

ß: LCR (2)

γ: --

γ: LCR (2)

α: PTZ00440

α: --

ß: --

ß: LCR

γ: --

γ: LCR

ß: DUF4092,
Peptidase_M60, M60-like

ß: M60-like, LCR

γ: DUF4092,
Peptidase_M60, M60-like

γ: M60-like, transmembrane
region, LCR

γ: Hypothetical
protein
α: Hypothetical
protein
ß: Hypothetical
protein
γ: Hypothetical
protein
α: OspB protein
ß: hypothetical
protein /*OspB
homolog
γ: hypothetical
protein /*OspB
homolog

Putative effectors

ORF34

ß: SslE/AcfD family
lipoprotein zinc
metalloprotease
γ: DUF4092
domain-containing
protein/sugar ABC
transporter substratebinding
protein/accessory

colonization factor
AcfD

ORF35

ß: MAVPRPIeRC_00042
γ: MAVPQPI_00035

ß: 81 YES SVM
γ: YES 72 SVM

ß: hypothetical
protein
γ: hypothetical
protein

ß: --

ß: --

γ: --

γ: LCR

ß: MAVPß: hypothetical
ß: YES 80 SVM
ß: -ß: -RPIeRC_00087
protein
γ: MAVPγ: hypothetical
γ: YES 87 SVM
γ: -γ: LCR
QPI_00081
protein
Prediction of T3SS2 effectors by pEffect..Gene names provided to the orthologs named strain RIMD2210633 VPaIα (NC_004605 region between
VPA1312 and VPA1395), designated as α, strain MAVP-R VPaIß (MF066647.2), designated as ß, and strain MAVP-Q VPaIγ (MF066646.1), designated
as γ. “+” = the presence of effector and predicted effector on VPaIα/ß/γ. “-” = the absence of effector and predicted effector on VPaIα/ß/γ. “~” = divergence
between orthologs found in VPaIß/γ compared to the characterized effector in VPaIα. Basic Local Alignment Search Tool (BLASTx) and protein domains
and motifs predicted from SMART (Simple Modular Architecture Research Tool)209 and NCBI’s Conserved Domain Database (CDD)210 are detailed.
LCR = Low Complexity Region; DUF = Domain of Unknown Function.
ORF81

Figure 2.1. Comparison of content and conservation in representative VPaIα, VPaIβ, and
VPaIγ. Named effectors from VPaIα (vopA/C/L/V/Z and VPA1380) and their homologs are light
green. Candidate T3SS2β effectors (including divergent vopV and vopZ homologs) are red. The
program pEffect and BLASTp searches predicted candidate effectors. Figure adapted from Xu et
al. 2017 107.
Protein domains and analogs predict function and support the identity of predicted T3SS
effectors
Whereas one predicted effector, ORF32, was identified by homology to a characterized
effector, the remaining four effectors, ORF34, 35, 76, and 81 were de novo predictions via Support
Vector Machines (SVM) machine learning 208,211 (Table 2.1). Attempts to assign potential names
to these four by identifying homologous proteins using in the NCBI non-redundant protein
database identified the unnamed predicted effectors only as hypothetical proteins. Three predicted
effectors (ORF32, 34, and 76) were homologous to named proteins present in other Vibrio spp.
including Vibrio cholerae, Vibrio harveyi, Vibrio diabolicus, Vibrio mimicus, and Vibrio
campbellii.
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Among the predicted effectors, only ORF32 was initially identified based on sequence
similarity-based inference by PSI-BLAST (Table 2.1). Though the identifying T3SS effector
protein EspS was from Citrobacter rodentium (35.7% sequence identity, 94% query coverage,
3x10-40 E-value) further analysis revealed ORF32 was homologous to the OspB effector encoded
by Shigella spp.

212

(35.2% sequence identity, 88% query coverage, 1x10-31 E-value), and more

strikingly to a previously identified T3SS2 effector from VPaIα, VPA1380 (43.5%, 93% query
coverage, E-value of 9x10-76)

166

. ORF32 and VPA1380 were not identified as homologs

previously107 based on the low deduced protein identities, but the high E-value supports that these
are evolutionarily related. EspS helps maintain physiological balance during mouse infection by
repressing colonic crypt hyperplasia

213

. OspB, in Shigella pathogens helps repress the host

inflammatory response via down-regulation of IL-8

214

, and activates the NFkB pathway

215

. In

contrast to OspB, which produced limited, stress-dependent toxicity in Saccharomyces cerevisiae,
the OspB homolog VPA1380 (with 50% similarity) was toxic in yeast

166

. Thus, researchers

predicted that VPA1380 might target different eukaryotic pathway than OspB during normal S.
cerevisiae growth

166

.

Next, to identify these putative effectors’ functional domains, the architecture of the deduced
proteins were analyzed by two protein domain prediction programs

209,210

. The deduced protein

sequence of ORF76 had no conserved domains. The only potential domains in ORFs 32, 35, and
81 were Low Complexity Regions (LCRs), whose biased amino acid composition can lead to more
predicted binding partners across different Protein-Protein Interaction (PPI) networks
LCRs have identified roles, but the functions of most are not known

216–220

216

. Some

. Previous studies of

repetitive sequences, such as those in LCRs, suggests that this genetic pattern enables rapid
adaptation to new environments 216,218,221,222. Although the LCRs in ORFs 32, 35, and 81 have no

41

further information, perhaps these domains provide a yet to be determined function. Of the five
predicted T3SS effectors, pEffect assigned the highest probability score to ORF34. Searches for
related proteins suggest ORF34 is most similar to proteins identified as sugar ATP-binding cassette
(ABC) transporter substrate-binding protein. Predicted functional domains in ORF34 include a
transmembrane helix region, a Pfam DUF (Domain of Unknown Function), and an M60-like
domain (Figure 2.2). Bacteria secrete T3SS effectors into either the plasma membrane or directly
into the cytosol of the target cell; thus, this transmembrane region of ORF34 could allow for
effector binding to eukaryotic membranes

223

. M60-like domains typically possess mucinase

activity, which could be beneficial in breaking down the protective mucin layer produced by
enterocytes to allow for better bacterial adhesion

224

. Pfam DUF4092 is in other Proteobacteria

such as Escherichia coli, Vibrio cholerae, Vibrio fischeri, and Photobacterium iliopiscarium 225.
Similarly to ORF34, 18 of the 20 known proteins with Pfam DUF4092 also contain the Peptidase
M60-like domain downstream, and most are identified as Accessory colonization factor (AcfD)
homologs. During infection, AcfD promotes efficient intestinal colonization in the human enteric
pathogens V. cholerae 226 and Enterotoxigenic E. coli (ETEC) 227. In V. cholerae, AcfD is a lipid
anchor at the cell membrane, which also hints at the function of the predicted transmembrane helix
region in ORF34. In ETEC, the AcfD homolog, YghJ, is a metalloprotease that influences
intestinal colonization of ETEC by degrading the major mucins in the small intestine

227

. The

similar functional domains as other enteric pathogens shed some light as to the possible function
of ORF34. The close proximity (37bp apart) and directionality of two putative effector genes,
ORF34 and ORF35, suggest these are likely co-transcribed under a single promoter’s control. No
transcriptional terminators were identified 228 within 300nts downstream of ORF35, but one was
identified after ORF34.
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Figure 2.2: ORF34 contains predicted domains that may influence successful colonization.
ORF34 domain prediction from SMART (Simple Modular Architecture Research Tool) 209. The
blue rectangle indicates a transmembrane region. Pfam DUF4092 is in the Protein family “Domain
of Unknown Function” 4092. The teal pentagon indicates the M60-like domain. The pink rectangle
indicates a Low Complexity Region (LCR).
There were no predicted domains for ORF76, but its possible function may be gathered from
its homology to known proteins. ORF76 was homologous to a conjugal transfer protein TraA of
V. parahaemolyticus (100% sequence identity, 99% query coverage, 7x10-164 E-value), and several
deduced TraA proteins from other members of the Vibrionaceae family. TraA is typically involved
in pilus biosynthesis and assembly during conjugation

229

. Understandably, pEffect identified

ORF76 as a potential T3SS effector since some T3SS apparatus proteins are identified as effectors
by pEffect. For example, the translocator VopD2 (VPA1361)

230

and translocon protein VopW

(VPA1345) 231 were both predicted by pEffect to be T3SS effectors via SVM (scores of 82 and 94
respectively). These proteins are part of the secretion needle and extend from the bacterial cell into
its target, similarly to TraA’s role as a pilin precursor protein

229

. Homology to TraA does not

suggest that ORF76 has a toxin-related role during infection, but further studies such as secretion
assays and animal studies would be necessary to make this determination. Interestingly though
ORF76 as a was not previously identified as homologous to to the VPaIα effector VopO
(VPA1329) based on sequenced identity (46.05% sequence identity, 99% query coverage), the
strong E-value (1x10-75) provides statistical support of evolutionary relatedness. During
gastrointestinal infection with V. parahaemolyticus, VPA1329 contributes to host epithelial
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disruption by activating the RhoA-ROCK signaling pathway, which induces actin stress fiber
formation 145. But, VPA1329 was not considered a primary effector during infection of rabbit illeal
145

. Due to the recent findings of the contribution of VopC in a mouse infection model 151, further

investigation into ORF76 is necessary to understand its role fully. Unlike with ORF32, 34 and 76,
searches for homologs provided little insight into the function of the remaining two effectors, ORF
35 and ORF81.
VPaIß and VPaIγ encode potential homologs of the VPaIα-encoded effectors critical for the
enterotoxicity of pandemic strains, VopV (VPA1357) and VopZ (VPA1336). Previous analysis
using Roary

232

indicated VopV and VopZ did not meet the 50% threshold used for identifying

homologs between VPaI even though divergent ORFs located in the same location and gene
neighborhoods in VPaIß and VPaIγ were still considered potentially analogous

11

. A closer

examination and comparison of the deduced VopV protein in VPaIα (VPA1357) to the potential
analog in VPaIγ (ORF61) indicates that even though they share only 40.3% protein sequence
identity with 60% query coverage, the accompanying E-value of 6x10-95 provides strong statistical
support of homology. Although the lower query coverage could be related to size differences of
the deduced VopV proteins (VPA1357 at 4869bp and ORF61 at 7209bp), size alone does not
account for this poor coverage. VopV encoded by VPA1357 possesses multiple domains, the
interspersed or long repeat domains (rep1/2/3) and C-terminal domain, that are crucial to VopV
induced enterotoxicity

139,141

. These domains bind to actin filaments and the actin-cross linking

protein filamin 139. Thereby bundling actin in the host cell leading to rearrangement of the apical
epithelial cell membrane and elimination of the actin-filled microvilli brush border, leading to
enhanced adhesion of V. parahaemolyticus to the host cell

139,141

. Alignment of VPA1357 and

ORF61 proteins indicate that these important domains in VPA1557 are either not present in ORF61
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or contain numerous amino acid composition changes. The large discrepancy in these important
domains could indicate that ORF61 does not have the same enterotoxic capabilities as its
characterized homolog VPA1357.
The VopZ analogs are relatively similar in size, with VopZ from VPaIα (VPA1336) 753bp and
the potential VopZ analog in VPaIγ (ORF44) 768bp. Despite their similarity in size, VPA1336
and ORF44 have only 27% protein percent identity (71% query coverage) though again, the strong
E-value (1x10-15) indicates evolutionary relatedness. V. parahaemolyticus induced diarrhea and
other intestinal pathology, but not colonization, in vivo relies on amino acids 38–62 in VPA1336
147

. When the proteins are aligned, only 32% of this important region in the VPA1336 sequence is

retained in ORF44. There is also a deletion of one amino acid and an insertion of four amino acids.
This divergence in sequence in this important domain in ORF44 from the characterized VPA1336
might contribute to changes in intestinal pathology during V. parahaemolyticus infection. Previous
studies indicate that truncation of VPA1336 after amino acids 38–62 resulted in the loss of V.
parahaemolyticus colonization of the small intestine

147

. Since this region is important for V.

parahaemolyticus colonization perhaps the large divergence in sequence from VPA1336
effectively removed this capability of ORF44. Since ORF61 and ORF44 on VPaIγ are so divergent
from their enterotoxic orthologs on VPaIα, this suggests that further investigation is needed to
assess which effectors contribute to V. parahaemolyticus pathogenicity.

Predicted effectors are toxic to eukaryotic cells
To examine putative effector toxicity towards eukaryotic cells, we used heterologous
overexpression in the yeast S. cerevisiae and quantified growth inhibition following protein
induction. Yeast is often used as part of T3SS effector characterization since they utilize conserved
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eukaryotic processes that are typical targets of T3SS effectors, such as cell signaling and
cytoskeletal dynamics, without immunity mechanisms that counteract T3SS effectors 233–235. Due
to this, while effector toxicity as inferred by growth attenuation by heterologous effector
expression in yeast, does not directly recapitulate all aspects of enterotoxicity or disease, the model
is an excellent initial screen to evaluate proposed effectors and gain initial insight into the role an
effector might have on their eukaryotic target.
During intracellular overexpression of each putative effector, relative toxicity was
quantified by their ability to inhibit yeast growth compared to negative (empty vector) and positive
(VopA) controls. When grown under inducing conditions, the ORF32 construct did not reduce
yeast growth, similarly to the yeast harboring the empty vector (Figure 2.3). In contrast, induction
of ORF35 and ORF81 dramatically reduced yeast growth. Expression of ORF34 and ORF76
moderately attenuated yeast growth. In congruence with previous studies 124, the VopA homolog
inhibited yeast growth, the VopC homolog did not attenuate yeast growth. Finally, VopL was not
previously evaluated for yeast toxicity, and its homolog from VPaIγ did not inhibit yeast in our
study.
Even though a key VPaIα effector, VopZ is highly divergent from gene products in the
same location in VPaIß/γ, these were both identified as putitive effectors and may be analogous
toxins, and thus both were evaluated for toxicity. Neither VopZ analog from VPaIα (VPA1336)
nor VPaIγ (ORF44) inhibited yeast growth. During V. parahaemolyticus infection, VopZ from
VPaIα promotes colonization by inhibiting the activation of the kinase TAK1, which disrupts cell
signaling cascades leading to phenotypes such as inflammation, distorted epithelial structure, and
mislocalization of tight junction proteins 125,147,163. Yeast do not exhibit these phenotypes, thus this
model cannot appropriately evaluate the effect of these proteins. While this does limit this model’s
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effectiveness for evaluating some characteristics of epithelial disease, the wide breadth of effectors
that the model can evaluate, such as those that alter the cytoskeleton and organelles, target MAPKsignaling cascades, or perturb vesicle trafficking warrants this as an effective preliminary assay
234

. Other assays useful in evaluating effectors whose effect cannot be visualized in yeast include

more laborious assays such as Western Blot analysis, cell-culture, and animal models. Despite the
minimal growth reduction conferred by ORFs 32 and 34, these effectors could still contribute to
disease if their eukaryotic target does not confer a similar phenotype in yeast, similar to the finding
of VopZ. Other models including cytotoxicity

122

and brush border remodeling139 of cultured

human colon cells, and animal infection models such as the rabbit ileal loop model 98,138 or a mouse
infection model151 are needed to address this issue. We did not evaluate VopV in this model due
to its large size and the repetitive nature of the sequence that thwarted our attempts to clone the
gene.
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Figure 2.3: Heterologous expression of putative effectors inhibit yeast growth. Serial dilutions
of yeast transformed with pYES2.1 plasmid harboring putative toxin (from VPaIγ or VPaIα) were
grown under non-inducing (glucose) and inducing (galactose) conditions. Data is representative of
three experiments performed in triplicate. All effectors except VPaIα VopZ were constructed from
ST631 clade II MAVP-Q harboring VPaIγ genomic DNA. VPaIα VopZ template DNA was ST3
MAVP-C harboring VPaIα genomic DNA.
Predicted effectors induce cytotoxicity in cultured human colon cells
Next, we assessed T3SS2-dependent cytotoxicity of each putative effector against cultured
Caco-2 colorectal tumor cells. Caco-2 cells were co-cultured with wild-type (wt) V.
parahaemolyticus and with mutant derivatives altered for T3SS ability. After co-culture, the
cytotoxicity of the Caco-2 cells was quantified (Figure 2.4). Effectors secreted by T3SS1
contribute to cytotoxicity towards Caco-2 cultured cells, but are unimportant for enterotoxicity and
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can mask the effect of T3SS2 effectors. For this reason, the vscN1 gene encoding the ATPase
powering secretion through the T3SS1 apparatus was deleted to disable T3SS1 effector secretion
prior to the generation of individual effector gene deletions. We included this derivative to
eliminate background cytotoxicity, allowing us to evaluate each putative effector’s contribution to
cytotoxicity. All V. parahaemolyticus strains were cultured in 0.04% bile before co-incubation
with Caco-2 cells to simulate gastrointestinal conditions and induce differential regulation of
virulence genes

236–238

. However, a recent study indicates that genes on VPaIγ in strain 04-1290

were not induced by bile, though the assertion that strain 04-1290 containing VPaIγ did not contain
bile-inducible VtrABC was not correct 107,238,239. In our study, V. parahaemolyticus growth in bile
increased cytotoxicity towards Caco-2 cells (data not shown), and thus bile was used for all
experiments. Elimination of VscN1 (ΔvscN1) did not significantly reduce cytotoxicity under the
conditions of our assays (Figure 2.4), as expected from previous data 9. This importantly alludes
to the substantial impact of toxic effectors from T3SS2 contributing to the cytotoxicity of Caco-2
cells, and the utility of the model. This is further borne out by the elimination of T3SS2 in the
T3SS1 mutant background, which significantly impaired cytotoxicity, reflective of an inability of
these bacteria to secrete T3SS2 toxins, again replicating previously published work 9. Following
this validation, we subsequently eliminated predicted T3SS2 effectors, as well as ORF61 (VopV)
and ORF44 (VopZ), and evaluated their impact on cytotoxicity. Notably, we did not generate
individual ORF34 or ORF35 deletions because we predicted that these ORFs are cotranscribed
under the control of a shared promoter, thus both ORFs were eliminated simultaneously generating
the mutant designated ΔORF34-35 .
Elimination of the OspB/VPA1380 homolog ORF32 did not attenuate cytotoxicity,
however, elimination of any of the remaining putative toxins, or the combined elimination of
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ORF34 and ORF35, significantly reduced cytotoxicity (P > 0.01) compared with either wild type
or the parental T3SS1 mutant. Taken together, these results along with the ability of these toxins
to inhibit yeast growth suggest that putative effectors ORFs 34-35, 76, and 81 are four of the genes
responsible for T3SS2-dependent cytotoxicity, along with the vopV and vopZ analogs (ORFs 61
and 44 respectively). Interestingly eliminating any singular putative toxin appears to reduce the
cytotoxicity to similar levels as preventing the secretion of all T3SS2 effectors. Since VPaIα
effectors work in concert to achieve their enterotoxic effect, we believe that our cytotoxicity model,
as a surrogate for enterotoxicity, could work similarly, in that deletion of one effector affects the
ability of other effectors to carry out their function.

wt

wt

ΔvscN1

ΔvscN1

ΔvscN2

ΔvscN2
ΔvscN1
ΔvscN1

ΔORF32
ΔORF76
ΔORF32 ΔORF34-35
ΔORF34-35 ΔORF76
ΔvscN1
ΔvscN1
ΔvscN1

ΔvscN1

ΔvscN1

ΔvscN1

ΔORF81

ΔORF81
ΔvscN1
ΔvscN1

ΔvopV

ΔvopV
ΔvscN1
ΔvscN1

ΔvopZ
ΔvopZ
ΔvscN1

ΔvscN1

Figure 2.4. Reduced cytotoxicity towards Caco-2 cells mirrors the difference in toxicity
towards yeast. The human colorectal tumor cell line, Caco-2 cells, were co-incubated with V.
parahaemolyticus strains defective in T3SS1, and harboring indicated ORF deletions. We predict
ORFs 34 and 35 are co-transcribed and thus deleted both simultaneously. Percent cytotoxicity,
estimated by the quantity of lactate dehydrogenase (LDH) in the well after co-culture, was
calculated by the following equation: [optical density at 490 nm (OD490) of experimental release OD490 of spontaneous release]/(OD490 of maximum release - OD490 of spontaneous release)*100%.
Spontaneous release is the amount of LDH released from the cytoplasm of uninfected cells. The
maximum release is the total amount of LDH released after the complete lysis of uninfected cells.
* = p <0.001 Tukey Kramer HSD for pair-wise comparisons. Data represents the mean ± standard
deviation from one experiment using five individual bacterial colonies per strain, performed in
triplicate. The experiment was repeated twice with similar results.
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Conclusion
Critical forces on microbial pathogen’s evolution are gene gain or loss, and recombination
of acquired genes

32,55,57–62

. Acquisitions of genetic material, such as virulence effectors, can

provide a fitness advantage beneficial to bacteria under certain conditions such as adaptation to
changing environmental conditions, enhancing virulence, or immune evasion

32,34,56,57,64–66

.

Virulence effectors can also undergo strong selection for either increasing allelic variation,
maintaining a beneficial allele, and removing deleterious alleles 240. Diversity in effector content
can be beneficial for bacteria, because each toxin has a particular function. While some may be
more important than others in a given environment, they all have a specific role that may benefit
the bacteria, especially when they work in concert 112,240,241.
In addition to confirming the presence of homologs of four named effectors in VPaIα
(VopV, VopZ, VopO and VPA1380) that eluded prior discovery, we also identified three T3SS2β
effectors encoded in VPaIγ and β without homologs in VPaIα, all of which may contribute to
disease caused by the most clinically prevalent strains in North America, including ST631 and
ST36. The protein domains and cytotoxicity induced by ORF34 suggest it could be an important
effector and promote enterotoxicity. The transmembrane anchoring, mucinase activity, and
enhanced colonization associated with these domains characterized in other enteric pathogens
suggest that ORF34 may contribute these same characteristics to V. parahaemolyticus during
infection. Mucus and mucins are the first line of defense for enterocytes

242,243

; thus, mucin-

degrading capabilities by V. parahaemolyticus would be extremely beneficial to infection success.
These predicted activities may also explain the lack of toxicity in yeast. The likely co-transcribed
protein ORF35 was toxic to yeast and likely contributed to Caco-2 cytotoxicity; however,
individual gene deletions are needed to identify if cytotoxicity was due to the synergistic effects
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of ORF34 and ORF35, or just ORF35. Caco-2 cells do not secrete mucins

244,245

, thus if mucin-

degradation is the primary role of ORF34, then the cytotoxic effect seen can be attributed to
ORF35. The quantification of mucus degradation after co-culture with a mucus-producing cell line
such as HT29-MTX could assess this hypothesis

244–246

. The cytotoxicity of ORF76 and ORF81

towards both yeast and human colon cells indicates that these effectors are toxic toward cultured
human colon cells, suggesting a potential role during infection in humans. ORF32 was the only
effector predicted by pEffect based on nucleotide sequence similarity to other known T3SS
effectors, but it did not inhibit yeast growth and is not cytotoxic towards cultured human colon
cells. Thus, we believe other models for ORF32’s characterization are more appropriate, and
further studies are needed. These effector’s impact in the models utilized lays important
foundational work towards virulence effector identification and characterization in VPaIγ. To
elucidate the contribution these effectors have towards disease, infection analyses such as human
colon cell brush border effacement 139, or gastrointestinal colonization and pathogenesis studies in
infant rabbits138,139 or mice 151 are necessary.
Identification of the virulence effectors in the prominent pathogenic V. parahaemolyticus
lineages in North America could aid in monitoring local populations. This, combined with tdh and
trh monitoring, can be translated into sensitive surveillance tools to identify the most important
emergent lineages, which can prevent negative publicity and reactive harvest closure of local
businesses

247–249

. These findings can also inform therapeutic interventions and novel vaccines

beneficial for individuals with an increased risk for infection

250

. This study identifies V.

parahaemolyticus T3SS effectors on VPaIβ and VPaIγ, but it does not fully characterize each
effector’s role during gastrointestinal infection. Though we do identify effectors encoded by VPaIβ
and VPaIγ, there are different lineages of VPaIγ that have evolved in geographically distinct
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populations, and strains that harbor these variants differ in clinical prevalence 11. T3SS effectors
on VPaIα are essential for disease, thus since there is variation in clinical prevalence among VPaIγ,
perhaps this is due to variation in their T3SS effectors. Further studies are needed to examine
whether the variation in these five T3SS effectors on VPaIβ and VPaIγ correlate with clinical
prevalence of their harboring strains.
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Materials and Methods
Bacterial and Yeast Strains, Media and Culture Conditions
The bacterial strains and plasmids used in this study are described in Table 2.2 and Table 2.3,
respectively. V. parahaemolyticus was routinely grown at 37°C in Luria-Bertani medium
supplemented with 2% NaCl (LBS)

251

or in defined minimal media

252

supplemented with

0.0058% K2HPO4, 0.1% NH4Cl, 0.01mM FeSO4, 0.1 mM Tris pH 7.4, 0.6% glycerol, 1x Artificial
Sea Water, 0.625µg/mL chloramphenicol, and tap water for trace minerals for transformation. E.
coli strains were grown at 37°C in Luria-Bertani medium (LB) as previously described

251

.

Antibiotics were supplemented for selection of mutations and plasmids at the following
concentrations for V. parahaemolyticus: 12 µg/ml gentamicin (Gen), 2.5 µg/ml chloramphenicol
(Chl), and 5 µg/ml erythromycin (Erm) and at the following concentrations for E. coli: 50 µg/ml
kanamycin (Kan), 100 µg/ml ampicillin (Amp), and 25 µg/ml chloramphenicol (Chl).
S. cerevisiae BY4742 (obtained from Clyde Denis,

253

) was maintained in yeast extract (1%)-

peptone (2%)-and dextrose (2%) medium (YPD) 253, and grown on Synthetic Complete Minimal
Media (SC-MM) made with Yeast Synthetic Drop-out Medium Supplements without uracil
(Sigma-Aldrich), supplemented with glucose at 2% once transformed with pYES2.1/V5-HisTOPO®. S. cerevisiae was grown at 28°C.

Bioinformatic Analyses
The annotated VPaIs, including VPaIα (from strain RIMD2210633, NC_004605 region between
VPA1312 and VPA1395), VPaIß (from strain MAVP-R, MF066647.2) and VPaIγ (from strain
MAVP-Q, MF066646.1), were analyzed by the pEffect online algorithm 208. The predicted T3SS
ORFs from pEffect were then submitted individually to the following programs according to their
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normal operating instructions: Basic Local Alignment Search Tool (BLASTx)
(Simple Modular Architecture Research Tool)
(CDD)

210

209

254

, SMART

, and NCBI's Conserved Domain Database

. To find potential terminators, the 300 nucleotide region following the stop codon of

ORF35 and ORF34 was submitted to the FindTerm (Softberry Inc.) 228 webpage application set to
standard operating instructions with the “All putative terminators” box checked.

Molecular genetic methodologies and plasmid construction
Strain Construction Overview
Targeted deletion mutants of V. parahaemolyticus strains were constructed through the process of
PCR Splicing by Overlap Extension (SOE)

255

wherein genes of interest were eliminated and

replaced with an antibiotic resistance cassette, the resulting constructs were cloned into plasmid
pCR2.1 TOPO (TOPO™ TA Cloning™ Kit, Thermo Fisher), which was subsequently used for
natural transformation. PCR SOE primers have 3’ complementary ends to the products intended
to fuse together (Table 2.2). During PCR cycling, the ends overlap and are extended into a single
molecule.

PCR SOE and cloning
Primers for generating constructs used in marker exchange mutagenesis were designed as
recommended 255. Oligonucleotide primers were synthesized by © Integrated DNA Technologies
(Coralville, IA). PCR cycling conditions were optimized using AccuStart II PCR SuperMix
(Quantabio, Beverly, MA). Genomic DNA from V. parahaemolyticus strain MAVP-Q, a ST631
clade II member containing VPaIγ, from VPaIγ, and strain MAVP-C, a pandemic ST3 strain
containing VPaIα,was used as a template to generate amplicons upstream and downstream of the
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gene of interest, whereas amplicons of the antibiotic cassettes were generated using plasmids
pBD4 and pEVS170 (Table 2.4). Genomic DNA was prepared by organic DNA extraction

256

.

Oligonucleotide primers for gene knockouts were designed to contain at least 400bp regions
flanking the gene of interest to enable efficient recombination (Table 2.3). Oligonucleotide primers
for the antibiotic cassette to replace the gene of interest were designed to contain the native
antibiotic resistance cassette promoter from the plasmid (Table 2.3). Analysis of the secondary
structure of primers was performed by NetPrimer (©PREMIER Biosoft). Gene knockouts and
antibiotic resistance genes were amplified from target DNA with Phusion® High-Fidelity DNA
Polymerase or Phusion® High-Fidelity PCR Master Mix (©New England Biolabs, Ipswich, MA)
according to ©New England Biolabs Inc. protocol. PCR SOE was performed as described

255

.

PCR SOE product was cloned into pCR2.1TOPO® and transformed into chemically competent E.
coli 10-beta cells (New England Biolabs®, Ipswich, MA) following Invitrogen pCR2.1TOPO®
(Invitrogen K202020) protocol. Plasmid DNA was purified using ©QIAGEN Plasmid Kit protocol
with house-made ©QIAGEN reagents. Confirmation that the constructs contained no PCR
generated errors was determined by sequencing using the Sanger method by ©GENEWIZ LLC
(South Plainfield, NJ, USA).

Competency Plasmid Construction
To enhance the competency of V. parahaemolyticus enabling the use of natural transformation for
strain construction, we designed and constructed a plasmid to express the native tfoX gene from V.
parahaemolyticus strain MAVP-Q under the control of the arabinose-inducible and glucoserepressible promoter PBAD along with the gene encoding the arabinose operon regulatory protein
araC gene (araC-ParaBAD-tfoX) into shuttle vector pEVS79, generating pSEE1. Briefly, primers
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were designed to clone the araC and its native promoter and a downstream ParaBAD promoter from
pSW7848, and in parallel to amplify the native V. parahaemolyticus tfoX from MAVP-Q, and the
two amplicons were fused using PCR SOE

255

. The resulting construct was cloned into

pCR2.1TOPO plasmid, which was propagated in E. coli One-Shot TOP10. Purified plasmids were
sequenced to confirm the constructs were correct and error-free by Sanger sequencing at
©GENEWIZ LLC (South Plainfield, NJ, USA). The araC-ParaBAD-tfoX cassette was subsequently
cloned from the resulting plasmid (pSEE21) into pEVS79 257 by restriction digest with SpeI and
XhoI (©New England Biolabs, Ipswich, MA) to move the cassette from pSEE21 to pEVS79 257,
resulting in the final plasmid pSEE1. pSEE1 was conjugated into V. parahaemolyticus using TriParental Mating with the helper plasmid pEVS104 as described

257

. Briefly equimolar

concentrations of mid-log phase E. coli harboring pSEE1, E. coli harboring pEVS104, and
recipient V. parahaemolyticus were individually washed in LBS and resuspended together in 20
µL LBS. The entire suspension was spotted onto LBS agar and grown overnight at 37°C. The
following day entire spot was collected, diluted, plated onto LBS+Chl2.5, and grown at 28°C
overnight to select for V. parahaemolyticus.

Transformation of V. parahaemolyticus
V. parahaemolyticus strains harboring pSEE1 were grown to turbidity in LBS and subsequently a
2% inoculum was used to grow an overnight culture at RT in minimal medium supplemented with
0.2% arabinose. Once cultures reached OD600 > 0.5, 0.5 mL culture was mixed with 2 µg of either
plasmid DNA or ~10 µg of genomic DNA that was sheared by freeze-thaw three times at -20°C,
and incubated at 28°C statically for 30 minutes. 0.5 mL LBS was added to the culture and was
incubated at 37°C for 20-60 minutes. Cells were pelleted and suspended in ~50 µl LBS broth.
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Equal volumes of transformant were plated onto three concentrations of antibiotic flanking
estimated optimal concentration (10/12/15 µg/ml gentamycin and 2.5/5/8 µg/ml erythromycin)
and grown at 37°C overnight. Colonies were re-streaked to a plate with a higher concentration of
antibiotic, grown at 37°C, then the colony screened by PCR to identify the presence of the
mutation. Mutants harboring pSEE1 were passaged at a 2% inoculum in LBS twice per day for
two days to lose plasmid.

Cytotoxicity Assay
Eukaryotic cell culture
Caco-2 cells were regularly maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
ATCC®) containing 10% (v/v) Fetal Bovine Serum (FBS, Sigma®) and Corning® AntibioticAntimycotic Solution at 37°C in 5% CO2.

Cytotoxicity measurements
Caco-2 cells at 80% confluency were washed in DMEM without phenol red + 10% FBS and seeded
25µL of cells at 315 cells/µl in 384-well plates and cultured for 48hr at 37°C in 5% CO2 to
confluency. Unmodified V. parahaemolyticus strains were streaked for isolation onto LBS agar,
ΔvscN1:Gen V. parahaemolyticus mutants were streaked for isolation onto LBS + 5 µg/ml Gen,
and ΔvscN1:Gen/Δ(gene of interest):Erm V. parahaemolyticus mutants were streaked for isolation
onto LBS + 5 µg/ml Erm. All V. parahaemolyticus strains were grown at 37°C until robust colony
growth. Five colonies of V. parahaemolyticus were grown overnight in LBS + 0.04% bile salts at
37°C in a roller drum. Cultures were washed twice in PBS and diluted to add 5µL of culture to
48hr Caco-2 cells at an MOI of 10. Three replicates per sample were added to Caco-2 cells. After
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6hrs of co-culture, the release of lactate dehydrogenase (LDH) into the medium was quantiﬁed by
using a CytoTox96® non-radioactive cytotoxicity kit (Promega®) according to the manufacturer’s
instructions. To quantify percent cytotoxicity, the LDH release was calculated with the following
equation: [optical density at 490 nm (OD490) of experimental release - OD490 of spontaneous
release]/(OD490 of maximum release - OD490 of spontaneous release)*100%. Spontaneous release
is the amount of LDH released from the cytoplasm of uninfected cells, whereas the maximum
release is the total amount of LDH released after the complete lysis of uninfected cells.
Statistical Analysis
Data from Caco-2 cytotoxicity assay represents the mean ± standard deviation from one
experiment using five individual bacterial colonies per strain, performed in triplicate. Pairwise
comparison across strains was performed utilizing Tukey Kramer HSD.
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Table 2.2: Strains used in this study
Strain

Description

Source of Reference

E. coli strains
DH5α

pEVS79

257

CC118lpir

pEVS104

257

TOP10

pSEE1

This study

One-Shot TOP10F’

Thermo Fisher®

10-beta cells

New England Biolabs®

V. parahaemolyticus
strains
MAVP-Q

WT

22

TBD

ΔvscN1:Gen

This study

TBD

ΔvscN1:Gen ΔvscN2:Erm

This study

TBD

ΔvscN1:Gen ΔORF32:Erm

This study

TBD

ΔvscN1:Gen ΔORF34-35:Erm

This study

TBD

ΔvscN1:Gen ΔORF85:Erm

This study

TBD

ΔvscN1:Gen ΔORF90:Erm

This study

TBD

ΔvscN1:Gen ΔvopV:Erm

This study

TBD

ΔvscN1:Gen ΔvopZ:Erm

This study

S. cerevisiae strains
his3-Δ1 leu2-Δ0 ura3-Δ0 lys2V0
Gen = gentamycin; Erm = erythromycin
BY4742
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Table 2.3: Oligonucleotides used in this study.
Primer name
Yeast Toxicity Assay
32YES FRBS2
32YES R
PrSEE52 34YES FRBS2 631_674
PrSEE53 34YES R2 631_674
35YES FRBS
35YES R
85YES FRBS
85YES R
90YES FRBS
90YES R
VopAYES FRBS
VopAYES R
VopCYES FRBS
VopCYES R
VopLYES FRBS
VopLYES R
VopZYES FRBS
VopZYES R
VopZYES FRBS
VopZYES R
VscNYES FRBS
VscNYES R
Competency Plasmid
PrSEE34 araC SOE AF
PrSEE35 araC SOE AR
PrSEE36 tfox SOE BF
PrSEE37 tfoX SOE BR

Target Gene

DNA template

Sequence

ORF32
ORF32
ORF34
ORF34
ORF35
ORF35
ORF76
ORF76
ORF81
ORF81
vopA
vopA
vopC
vopC
vopL
vopL
vopZ VPaIα
vopZ VPaIα
vopZ VPaIγ
vopZ VPaIγ
vscN2
vscN2

MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-C gDNA

AAAATGGCTATCTCTTTAACCGGATGTTT
GGTCAGAGCCTCATTGTTGATATTAGTCC
TTGATGGTTTGTTTTTCAGGTTTTTTC
TACAACTAGTCTCCAGCCTAATGTACCGT
GAAATGGGTATTATGATTCCTACATTCAACAGAG
CTAAAATCAAATCCTTTCTATCAATGTTCACT
ACTATGGCTTTAAATAAAATAAACCCTATTCAGT
CAGGAAACTCTACTAACACAAAAGAAGCC
AAAATGGTAATACAAAGCCAAAGACTGAGA
TTACCATATAATACCATGTTCACGAAGTATC
GACATGGATGTCGATAGTAAAGCAGGACC
AGAGAAGTCACTCACTATTCACACCGCA
AACATGGTAGAATTAAAGCAAATATTTA
CTACGCTAATTTGACTACTTTACTTTG
AGACGATGGTTAAGTCAACCTTTA
TTAAGACAATTTTGCTGCCA
ATTATGGCTGGGTATACTGATGTAAAACCGT

MAVP-C gDNA

ATCAAGAACTGTCATGGCTTTCCTCTA

MAVP-Q gDNA

ATTATGGCTGGGTATACTGATGTAAAACCGT

MAVP-Q gDNA

ATCAAGAACTGTCATGGCTTTCCTCTA

MAVP-Q gDNA
MAVP-Q gDNA

GTGATGGTACAGCACTATTTTAAGGTCAAGGA
TATATCAATAAGCTGACCAAATTCTCTCCAT

araC
araC
tfoX
tfoX

pSW7848
pSW7848
MAVP-Q gDNA
MAVP-Q gDNA

TGCTCTGCGAGGCTG
TTGACCTCTTTAATCTGAATAACGGGTATGGAGAAACA
TGTTTCTCCATACCCGTTATTCAGATTAAAGAGGTCAA
AACGATGACGATTGGACA

Genetic Knockouts
Puskar's vscN1 AF
PrSEE10 vscN1-GmAR2
PrSEE13 GmF pBD4
PrSEE14 GmR pBD4
PrSEE9 VSCN1-GmBF2
PrSEE11 VscN1-GmBR2
PrSEE12 VscN1-GmCF2
Puskar's vscN1 CR
PrSEE69 631_vscN2_Erm AF
PrSEE71 vscN2_Erm AR
PrSEE72 vscN2_Erm BF
PrSEE73 vscN2_Erm BR
PrSEE74 vscN2_Erm CF
PrSEE75 vscN2_Erm CR
PrSEE76 32_Erm AF
PrSEE77 631 32_Erm AR
PrSEE78 631 32_Erm BF
PrSEE79 631 32_Erm BR
PrSEE80 631 32_Erm CF
PrSEE81 631 32_Erm CR
ORF34.5SoAF
ORF34.5SoAR
ORF34.5SoBF
ORF34.5SoBR
ORF34.5SoCF
ORF34.5SoCR
PrSEE41 ORF85 AF

vscN1
vscN1
GenR
cassette
GenR
cassette
GenR
cassette
GenR
cassette
vscN1
vscN1
vscN2
vscN2
ErmR
cassette
ErmR
cassette
vscN2
vscN2
ORF32
ORF32
ErmR
cassette
ErmR
cassette
ORF32
ORF32
ORF34-35
ORF34-35
ErmR
cassette
ErmR
cassette
ORF34-35
ORF34-35
ORF76

MAVP-26 gDNA
MAVP-26 gDNA
pBD4 plasmid
prep
pBD4 plasmid
prep
PCR product

ATTTTCTGTTCTATTGCCACC
AGGCGACAAGGTGCTGAATAGAAAGGATGG
TCAGCACCTTGTCGCCT

PCR product

TGGGCACGAGCAAATTGTTAGGTGGCGGTA

MAVP-26 gDNA
MAVP-26 gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA

TACCGCCACCTAACAATTTGCTCGTGCCCA
CTTTGGTTTTATGGGCTTG
GAACGCCCGATGAAGT
GTTTCCGCCATTCTTTGGTGTCTTGATATGACTCCTT
AAGGAGTCATATCAAGACACCAAAGAATGGCGGAAAC

MAVP-Q gDNA

AGACAGCCGAACGTACTCCTTTACAAAAGCGACTCATAGA

MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
pEVS170

MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
pEVS170

TCTATGAGTCGCTTTTGTAAAGGAGTACGTTCGGCTGTCT
TGATACCCAGTCATAATAAATG
AGGTATTACTCAAGAAGGACTGT
GTTTCCGCCATTCTTTGAGTGTTAGTTGTGTTATGTTGTT
AACAACATAACACAACTAACACTCAAAGAATGGCGGAAA
C
GTCCACTTCAGAATACATTGTTTACAAAAGCGACTCATAG
A
TCTATGAGTCGCTTTTGTAAACAATGTATTCTGAAGTGGAC
AGACACCAGCACTCACGA
ATAACAACGGTTGATTTAATACTCTT
GTTTCCGCCATTCTTTGCTAACTCTGTTGAATGTAGG
CCTACATTCAACAGAGTTAGCAAAGAATGGCGGAAAC

pEVS170

GTTCTAACCATAGGACTGATTTACAAAAGCGACTCATAGA

MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA

TCTATGAGTCGCTTTTGTAAATCAGTCCTATGGTTAGAAC
ACCTTGCTCCTTAATTTGCCT
TGCCATTTACCTGTGACAT

pEVS170

AATTGTTAGGTGGCGGTA
CCATCCTTTCTATTCAGCACCTTGTCGCCT

PrSEE42 ORF85 AR
PrSEE43 ORF85 BF
PrSEE44 ORF85 BR
PrSEE45 ORF85 CF
PrSEE46 ORF85 CR
G88SoAF2
G88SoAR
G88SoBF
G88SoBR
G88SoCF
G88SoCR2
QVopVSoAF
QVopVSoAR
QVopVSoBF
QVopVSoBR
QVopVSoCF
QVopVSCR
Q44SoAF
Q44SoAR
Q44SoBF
Q44SoBR
Q44SoCF
Q44SoCR
Erm = erythromycin; Gen = gentamycin

ORF76
ErmR
cassette
ErmR
cassette
ORF76
ORF76
ORF81
ORF81
ErmR
cassette
ErmR
cassette
ORF81
ORF81
vopV
vopV
ErmR
cassette
ErmR
cassette
vopV
vopV
vopZ VPaIγ
vopZ VPaIγ
ErmR
cassette
ErmR
cassette
vopZ VPaIγ
vopZ VPaIγ

MAVP-Q gDNA
pEVS170

GTTTCCGCCATTCTTTGACTACGCTAATTTGACTACTT
AAGTAGTCAAATTAGCGTAGTCAAAGAATGGCGGAAAC

pEVS170

TTCGCATCTGATTCAACTTTACAAAAGCGACTCATAGA

MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
pEVS170

TCTATGAGTCGCTTTTGTAAAGTTGAATCAGATGCGAA
CATACAATGAATACCTCCACA
TGCCCATTCAAATACGCT
GTTTCCGCCATTCTTTGTATTAACATTTTTATCCG
CGGATAAAAATGTTAATACAAAGAATGGCGGAAAC

pEVS170

GGATGTATTTCGGGTTGTTTACAAAAGCGACTCATAGA

MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
pEVS170

TCTATGAGTCGCTTTTGTAAACAACCCGAAATACATCC
GTTATTGACACTGATAGTGGCTT
CGATGACTCCCGATTTCCA
GTTTCCGCCATTCTTTGCTATTTATCATATTAAAACCTCA
TGAGGTTTTAATATGATAAATAGCAAAGAATGGCGGAAAC

pEVS170

CGGAATCTCATAATCAGACTTTACAAAAGCGACTCATAGA

MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
MAVP-Q gDNA
pEVS170

TCTATGAGTCGCTTTTGTAAAGTCTGATTATGAGATTCCG
ATCATATAGACTCCAAGACACCTC
AGGAGTACGTTCGGCTGTCT
GTTTCCGCCATTCTTTGATACCCAGTCATAATAAATG
CATTTATTATGACTGGGTATCAAAGAATGGCGGAAAC

pEVS170

GAAATACTCACCATCGAGTTTTACAAAAGCGACTCATAGA

MAVP-Q gDNA
MAVP-Q gDNA

TCTATGAGTCGCTTTTGTAAAACTCGATGGTGAGTATTTC
AGTGCTAATCCTGTTCAAGTGG

Table 2.4: Plasmids used in this study
Plasmid

Description

Relevant characteristics

Reference

pEVS79

moderate suicide vector in V. parahaemolyticus

V. fischeri suicide cloning
vector, ChlR, TetR

257

pSW7848

pBAD promoter

258

pSEE1

competency plasmid, moderate suicide vector in V.
parahaemolyticus
pCR2.1-TOPO: araC-ParaBAD-tfoX

ChlR, R6K γ-ori-based suicide
vector, ccdB toxin gene under
the control of an arabinoseinducible and glucoserepressible promoter PBAD.
ChlR
KanR

This Study

Competency Plasmid

pSEE21

This Study

Genetic Knockouts
pBD4

Gen cassette

ErmR

259

pEVS170

Erm cassette

ChlR, mini-Tn5-Erm, oriVR6K
oriTRP4 KanR

260

pCR2.1-TOPO

cloning vector

KanR

Thermo Fisher
Scientific

pEVS104

helper plasmid for TPM

Conjugative plasmid with tra
and trb genes

257

pSEE2

pCR2.1-TOPO:ST631vscN1::Gen vscN1 gene knockout

KanR

This Study

R

R

This Study
This Study

pSEE3

pEVS79:ST631vscN1::Gen vscN1 gene knockout on
moderate suicide vector

Chl , Gen

pSEE4

pCR2.1-TOPO:ST631vscN2::Erm ST631 vscN2 knockout

ChlR, ErmR

pSEE5

pCR2.1-TOPO:ST631ORF32::Erm ST631 ORF32 knockout

R

R

This Study

R

R

Chl , Erm

pSEE6

pCR2.1-TOPO:ST631ORF34-35::Erm ST631
ORF34/ORF35 knockout

Chl , Erm

This Study

pSEE7

pCR2.1-TOPO:ST631ORF76::Erm ST631 ORF76 knockout

ChlR, ErmR

This Study

pSEE8
pSEE9

pCR2.1-TOPO:ST631ORF81::Erm ST631 ORF81 knockout
pCR2.1-TOPO:ST631ORFVopV::Erm ST631 VopV
knockout

R

R

This Study

R

R

This Study

Chl , Erm
Chl , Erm

pCR2.1-TOPO:ST631ORFVopZ::Erm ST631 VopZ knockout

ChlR, ErmR

This Study

pYES2.1-V5-HisTOPO
pSEE11

cloning vector

GAL1 promoter

pYES2.1-V5-His-TOPO:ST631ORF32 ST631 ORF32
expression vector

GAL1 promoter

Thermo Fisher
Scientific
This Study

pSEE12

pYES2.1-V5-His-TOPO:ST631ORF34 ST631 ORF34
expression vector

GAL1 promoter

This Study

pSEE13

pYES2.1-V5-His-TOPO:ST631ORF35 ST631 ORF35
expression vector

GAL1 promoter

This Study

pSEE14

pYES2.1-V5-His-TOPO:ST631ORF76 ST631 ORF76
expression vector

GAL1 promoter

This Study

pSEE15

pYES2.1-V5-His-TOPO:ST631ORF81 ST631 ORF81
expression vector

GAL1 promoter

This Study

pSEE16

pYES2.1-V5-His-TOPO:ST631VopA ST631 VopA
expression vector

GAL1 promoter

This Study

pSEE17

pYES2.1-V5-His-TOPO:ST631VopC ST631 VopC
expression vector

GAL1 promoter

This Study

pYES2.1-V5-His-TOPO:ST631VopL ST631 VopL
GAL1 promoter
expression vector
pSEE19
pYES2.1-V5-His-TOPO:ST631VopZ ST631 VopZ
GAL1 promoter
expression vector
pSEE20
pYES2.1-V5-His-TOPO:ST3VopZ ST3 VopZ expression
GAL1 promoter
vector
Gen = gentamycin; Erm = erythromycin; Chl = chloramphenicol; Kan = kanamycin; Tet = tetracycline

This Study

pSEE10
Yeast Toxicity Assay

pSEE18

This Study
This Study
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Abstract
Vibrio parahaemolyticus is an emergent human pathogen that is the primary cause of
seafood-borne bacterial disease in the United States (US) and worldwide. Cases of V.
parahaemolyticus infection have increased recently, especially from the North Atlantic Ocean.
Most V. parahaemolyticus clinical cases harbor one of three evolutionary related, yet distinct
Vibrio Pathogenicity Islands (VPaIs): VPaIα (tdh+), VPaIβ (trh+), or VPaIγ (tdh+/trh+). Strains
harboring VPaIα cause the most infections globally, but VPaIγ-harboring strains cause most US
infections. Of the different VPaIγ lineages identified thus far, tdh3-VPaIγ is most frequently
associated with disease whereas tdh5-VPaIγ are more often associated with strains from the
environment. In this study, we provide evidence that effectors from tdh3-VPaIγ and tdh5-VPaIγ
are evolutionarily divergent, and variation impacts effector toxicity, which may enhance
environmental fitness. This work lays the foundation for understanding how the unique
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environmental and population context of each VPaIγ lineage shaped the evolution of differing
degrees of toxicity that promote host fitness.

Introduction
Vibrio parahaemolyticus is an important human pathogen that is the primary cause of
seafood-borne bacterial infections in the United States and worldwide 10,18,261. V. parahaemolyticus
populations are diverse, and the majority of strains are harmless to humans 10,18. Human infection
with V. parahaemolyticus causes inflammatory gastroenteritis through the production of secreted
toxins encoded by one of three evolutionarily distinct mobile Vibrio Pathogenicity Islands (VPaIs)
identified as VPaIα, VPaIß, and VPaIγ 65 containing a Type Three Secretion System (T3SS) (see
Chapter 1 Figure 1.1 and Xu et al. 2017 107) 75,98,105–107. These VPaI each confer production of an
array of toxins; however, only a few of these toxins are known to contribute to enterotoxicity.
Though the VPaIs also encode two hemolysin genes, the thermostable direct hemolysin (Tdh) and
thermostable related hemolysin (Trh), both of which are helpful in identifying presence and
identity of different VPaIs, neither are key virulence factor for gastric disease 6,8,71–78.
Populations of V. parahaemolyticus harboring any one of the three VPaI are typically in
distinct, but non-uniform, geographic locations worldwide. Strains harboring VPaIα (tdh+), first
identified as VPaI-7

106

in strain RIMD2210633, and especially pandemic V. parahaemolyticus

known as Sequence Type (ST) 3 or serovar O3:K6 105, are prevalent in Asia and cause the majority
of infections globally

105

. Besides causing two outbreaks and sporadic infections, ST3 has not

established long-term populations along the Atlantic coastal areas of North America
26,45,173,176,178,185–188

. The most clinically prevalent STs causing infections in the United States,

harbor VPaIγ (tdh+/trh+) or less frequently VPaIß (trh+)
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19,39,40,65,190

. These related VPaI are

functionally analogous to but divergent from VPaIα, with limited shared content
11,65,98,107,109

65

. VPaIγ

contains genetic elements from both VPaIα and VPaIß 107, but displays a core content

orthologous and syntenous with VPaIß

97,107

and shares the same array of predicted T3SS2

effectors, only some of which are conserved in VPaIα (see Chapter 2 Figure 2.1 and Xu et al. 2017
107

). Thus far, experimental evidence links only three of the eight toxins encoded by VPaIα, VopV,

VopZ, and most recently VopC, to gastrointestinal disease. Both VPaIß and VPaIγ encode VopC.
Since the genes that are analogous to the VopV and VopZ toxins are so divergent from the
characterized toxins in VPaIα, toxins other than VopV and VopZ, conserved between VPaIß and
VPaIγ, may be critical for disease.
Historically, V. parahaemolyticus rarely caused infections from sources in the Northeast
United States; thus, there was a long-held belief that the North Atlantic’s environmental conditions
did not sustain pathogenic populations

33,44

. However, recently, infections associated with North

Atlantic harvested shellfish have increased. This trend coincided with warmer than usual ocean
temperatures in the region and the incursion and establishment of non-native lineages from the
Pacific Northwest and the Gulf of Mexico 8,22,48,49. Non-natives harboring VPaIγ include several
Paciﬁc derived pathogenic lineages (ST36, ST43, and ST636) 39,40,107, and long-time residents of
the Gulf of Mexico or Atlantic (ST34, ST110, and ST308) 22,53,60,190,192. However, not all of these
strains cause human infections, and those that have evolved among the Pacific population are more
clinically prevalent in the Northeast US, whereas those arising in the Atlantic and Gulf of Mexico
are less clinically prevalent 11. It is noteworthy that the originating population corresponds more
strongly with clinical prevalence than even VPaI type, as strains harboring VPaIγ reside in both
populations, and have invaded the Northwest Atlantic.
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Of the seven identified tdh alleles, four, including tdh3, tdh5, tdh6, and tdh7, are harbored
by VPaIγ suggesting the potential that these are distinct VPaI lineages evolving in parallel that,
due to the mobility of strains and horizontal nature of VPaI movement, are now globally distributed
(Figure 3.1). VPaIγ that harbor the tdh3 allele predominate among the North Pacific population of
V. parahaemolyticus (blue population block in Figure 3.1). These most notably include all
members of the ST36 clonal complex

11

(ST36, ST38, ST39, and ST59) and several unrelated

lineages isolated in the Pacific, including ST50 and ST636. In contrast, VPaIγs that harbor a tdh5
allele predominate among the longstanding Gulf of Mexico and the Atlantic Ocean populations
(red and purple populations in Figure 3.1) including ST34, ST110, and ST674

11,22,107,190,198

.

Importantly, V. parahaemolyticus harboring tdh3-VPaIγ, even those that acquired this VPaI
relatively recently (e.g., ST631), are clinically prevalent, whereas no lineage harboring tdh5-VPaIγ
is clinically prevalent even though they are frequently cultured from the environment

11

. Strain

lineages harboring tdh6- and tdh7-VPaIγ are among several of the global populations, including
ST308, ST23, ST1123, and ST676 (Figure 3.1), but, notably, very few of these caused repeated
infections. Specifically ST43, a lineage that likely arose in the Gulf of Mexico (red population in
Figure 3.1) based on population structure analysis, but that translocated and evolved among the
tdh3-VPaIγ strains of the Pacific population (blue population in Figure 3.1), harbors the tdh7VPaIγ whereas ST23, a Gulf of Mexico residential lineages also harbors a tdh7-VPaIγ 11,39,40,53.
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Figure 3.1: Population origin and global distribution of VPaIs. Global population structure of V. parahaemolyticus from
whole genomes evaluated in the R statistical package LEA262. tdh alleles harbored on VPaIγ designated below VPaI blocks.

V. parahaemolyticus harboring any of the four VPaIγ types (based on tdh allele) have invaded,
and some of these are causing infections from US Atlantic coastal waters

11

. Furthermore,

genomics analyses suggest these non-indigenous lineages have donated their VPaIs to the local V.
parahaemolyticus residents

11

. There is a pattern of variation in clinical and environmental

prevalence in pathogen lineages correlated with the VPaIγ lineage they harbor. Since each VPaIγ
variant originated from different geographic locations, this suggests a possibility that the
population in which these VPaIγ variants evolved could have influenced virulence potential they
confer 11. Perhaps, then since the T3SS2 toxins confer virulence, perhaps T3SS2 effector variation
underlies the differences in clinical prevalence.
Opportunistic pathogens, such as V. parahaemolyticus, evolve in the environment, and the
"coincidental evolution hypothesis" suggests that maintenance of virulence factors is a response to
selective environmental pressures instead of for virulence against humans 263. One of the leading
mortality factors of bacteria in marine and freshwater systems is grazing by phagotrophic protists
264–267

. In response to protozoan predation, virulence mechanisms as defense strategies have

evolved in bacteria to combat this selective pressure

268

. Extracellular pathogens such as V.

parahaemolyticus, utilize toxin secretion and bioﬁlm formation to avoid internalization by
protozoan predators and phagocytes 263. Perhaps variation in the novel effectors encoded by VPaIγ
and linked to population in which the lineages harboring these VPaI evolved might be due to
differences in environmental conditions such as protozoan predation.
This study aims to compare the T3SS2 effectors from VPaIγ through analysis of population
and lineage phylogenetics, assess recombination patterns and effector selection, and utilize
functional models to elucidate the drivers of the variance in clinical and environmental prevalence
of these islands in the North Atlantic.
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Results
VPaIγ variation arose in geographically distinct populations
Analysis of the distribution of VPaIs among clinical isolates (2010-2016), updated from work
in Xu 2017 11, exemplifies that not all VPaIγ-harboring strains are equally prevalent (Table 3.1).
tdh5-VPaIγ is rare among clinically prevalent strains, but it is in environmental isolates fairly
commonly. tdh3-VPaIγ is in two unrelated sequence types (ST36 and ST631) that cause most
infections in the Northeast United States.
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Table 3.1: Demographics of Northeast United States pathogenic V. parahaemolyticus. Infections reported in
four Northeast US States (ME, NH, MA, and CT) between 2010 and 2016, sorted by Vibrio Pathogenicity Island
(VPaI) and hemolysin content. Note that not all infections were traced to local sources. The environmental
prevalence of strains harboring VPaIs is based on routine surveillance.

ST
3
36
631
631
631
43
636
1127
110
34/324
674
674
308
12
162
194
809
1716
1123
8
23
749
1295
134
741
98
1205
1561
1717
1725

Clinical isolates
2
91
24
1
0
5
4
4
3
2
0
1
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1

Environmental Isolates
0
1
0
2
1
0
0
0
0
2
4
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
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VPaI
α
tdh3-γ
tdh3-γ
ß
none
tdh7-γ
tdh3-γ
ß
tdh5-γ
tdh5-γ
tdh5-γ
none
tdh6-γ
ß
none
none
ß
ß
ß
ß
tdh7-γ
tdh6-γ
none
none
none
ß
none
none
none
α

To understand this relationship between tdh allele and prevalence, we built phylogenetic
trees of the tdh genes to glean the evolutionary relationships of the different alleles (Figure 3.2A).
This analysis exemplifies the distinctive phylogenetic signatures of tdh alleles encoded by VPaIγ
that differ from tdh1 and tdh2 harbored by VPaIα (Figure 3.2A). Though tdh3 and tdh5 clearly
represent divergent lineages, tdh6 most recently evolved from a common ancestor with tdh3,
whereas tdh7 and tdh4 share ancestry with tdh5. Though the phylogenetic signatures of tdh alleles
could mean that there are four distinct lineages of VPaIγ (Figure 3.2A), when the entire VPaIγ
sequences are used for constructing phylogenies and compared with the tdh gene phylogenies,
tdh3-VPaIγ and tdh5-VPaIγ are again phylogenetically distinct. Curiously tdh7-VPaIγ do not form
a single clade; rather these VPaIγ group with other VPaIγ by population, where the tdh7-VPaIγ
harbored by Pacific residential ST43 groups most closely with the Pacific dominant tdh3-VPaIγ,
and the tdh7-VPaIγ harbored by Gulf of Mexico resident strain ST23 groups with the tdh5-VPaIγ,
also from Atlantic or Gulf of Mexico residential strains (Figure 3.2B). This pattern of whole island
phylogenies that differs somewhat from tdh allele phylogenies underscores the evolutionary
influence of local populations.
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Figure 3.2A. Unique tdh alleles associate with each VPaIγ lineage; clinical prevalence
correlates with tdh3-containing VPaIγ whereas environmental prevalence correlates with
tdh5-containing VPaIγ. Maximum likelihood (ML) phylogenetic tree of tdh alleles from highquality genomes on the National Center for Biotechnology Information (NCBI) database. Alleles
are colored red to indicate those encoded in the pandemic island, VPaIα. tdh alleles prevalent in
either clinical or environmental isolates from the Northeast United States coastal areas are
colored green and blue.
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tdh3

tdh7
tdh6
tdh5
tdh7

Figure 3.2B: tdh3-VPaIγ and tdh5-VPaIγ are distinct lineages. Maximum Likelihood (ML) tree
constructed using the Jukes-Cantor model with 1000 bootstrap resamplings of VPaIβ and VPaIγ
from select genomes constructed on sequences corresponding to VPaIγ of ST631 strain MAVPQ.
Geographic signatures in the patterns of recombination among and between different
lineages of VPaIγ suggest they evolved differently in different populations
Xu et al. examined the short-term evolution of the four types of VPaIγ, identified loci with
convergent variation, and determined island relatedness based on the non-recombining regions
using the bioinformatics program Gubbins

11,68

. This analysis identified that the Northwest

Atlantic native V. parahaemolyticus ST631 harbored a tdh3-VPaIγ related to and derived from the
same population as the "hypervirulent" Pacific-native ST36, and not the tdh5-VPaIγ that is more
typical of Atlantic or Gulf of Mexico V. parahaemolyticus populations

11

. Their results also

identified patterns of clustered SNPs between the four VPaIγ types 11. Further analysis of this data
indicates several regions of the VPaIγ exhibit population-specific patterns of homoplasy indicative
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of either recombination or convergence (Figure 3.3). This could help explain the unresolved
common ancestry tdh7-VPaIγ that has been blurred by the geographic separation of host strains
(ST23 and ST43).
The VPaIß/VPaIγ maximum likelihood (ML)-tree built with all SNPs (Figure 3.2B), or
built only with non-recombining SNPs (Figure 3.3) indicate the common ancestry of tdh3-VPaIγ,
regardless of the strain lineage or population (Atlantic or Pacific). However, phylogenies of tdh7VPaIγ constructed using variation only in non-recombining regions produced unexpected topology
differences for strains that evolved in the Pacific compared to those that evolved in the Atlantic.
Specifically, when variation excluded recombining regions (Figure 3.3) tdh7-VPaIγs branch by
geographic population in which they evolved, perhaps reflective of localized adaptation tied to
variation in non-recombining regions. Furthermore, the tdh7-VPaIγ from ST43 that evolved in the
Pacific displays recombination patterns similar to that of the Pacific-native tdh3-VPaIγ potentially
resulting from between island recombination. The tdh7-VPaIγ that evolved in the Gulf of Mexico
displays recombination patterns similar to that of the Gulf of Mexico population tdh5-VPaIγ.
Interestingly, one of the four novel T3SS2 toxins (see Ch. 2), Open Reading Frame (ORF) 76
which is nearby the VopC toxin that is linked to gastric disease caused by ST3, is located in a
region of elevated SNP density in the tdh5-VPaIγ, indicative of recombination within the tdh5VPaIγ clade. The first half of a second T3SS toxin, ORF35, is in a recombination region within all
four VPaIγ clades.
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tdh7

tdh3

tdh5
tdh7
tdh5
tdh6

Figure 3.3: Geographic signatures of recombining regions of VPaIγ and predicted toxin
genes constructed with Gubbins. ML phylogeny was built on SNPs identified in nonrecombining regions (non-colored regions) and excluded regions of recombination exhibiting a
higher SNP density (colored blocks) 68. Red blocks indicate recombination within a clade of related
isolates, whereas blue blocks indicate recombination with isolates that were absent from the
analysis. Strains are colored by Sequence Type (ST). “PaI” designation after strain name indicates
that just the VPaI sequence was used in the analysis. Isolates are colored by sequence type using
a uniform coloring scheme as in Figure 3.2B and Figure 3.4.
Next, we investigated in more detail whether the phylogeny of putative effectors exhibited
the same topology as the entire island to evaluate whether the tree topology group the genes by
their historical lineages or local environments. We compared effector sequences from clinical
isolates harboring, tdh3-VPaIγ, tdh5-VPaIγ, tdh7-VPaIγ, and VPaIß isolated in the northeast
United States between 2010 and 2016. ML trees were constructed for each putative effector from
isolates representing STs and VPaIs that either commonly cause infections or prevail
environmentally in the Northeast United States (Table 3.1, Figure 3.2B). Effectors from the
clinically prevalent/environmentally infrequent STs (ST36, ST631 clade II, and ST636) harboring
tdh3-VPaIγ diverge from the orthologous effectors present in environmentally prevalent/clinically
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infrequent STs (ST674 and ST34) harboring tdh5-VPaIγ. The divergence between tdh3-VPaIγ and
tdh5-VPaIγ effector orthologs is most notable in the ORF76 phylogeny. Effectors from tdh6- and
tdh7-VPaIγs did not show as strong of patterns in their evolutionary relationships like the other
VPaIγ effectors.
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A. ORF32

B. ORF34

C. ORF35

D. ORF76

E. ORF81
volution of some T3SS2 effectors differs from the evolution of their whole VPaI.

Figure 3.4: The e A-E) Maximum-likelihood gene trees of putative effectors ORF32, ORF34,
ORF35, ORF76, and ORF81. tdh3-VPaIγ: MAVP-Q=ST631 clade II, MAVP-26=ST36, MAVP50=ST636, tdh5-VPaIγ strains include CT4291=ST674 and CTVP19C=ST34/324, tdh6/7-VPaIγ
strains include MAVP67=ST308 and MAVP71=ST43, and VPaIβ strains include
MAVP25=ST1127, MAVP-R=ST631 clade I. 100 bootstraps were run and bootstrap value shown
for each branch. The homologs used as outgroups for all five effectors were chosen based on high
80

sequence identity and 99% query coverage when using the effectors from strain MAVP-Q as a
query in BLASTn. Outgroup percent sequence identity corresponding to each ORF in MAVP-Q
for ORF 32/34/35/76/81 were 68.28%, 98.49%, 89.6%, 86.03%, and 68.28% respectively.
tdh3-VPaIγ and tdh5-VPaIγ are very similar in structure, with a few striking differences
(Figure 3.5). tdh5-VPaIγ (from strain CT4291) contains ten more ORFs than tdh3-VPaIγ (from
strain MAVP-Q), and several of these additional genes encode RTX toxin components that are
conserved in VPaIβ (data not shown) suggesting they were potentially lost from tdh3-VPaIγ.
Homologous effectors are slightly divergent, as indicated by a decreased BLASTn percent identity.
In the gene map, regions that flank ORF76 are divergent, and these regions correspond to areas
identified by the prior analysis as having undergone recombination in tdh5-VPaIγ lineages.
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Figure 3.5. Comparison of content and conservation in tdh3-VPaIγ and tdh5-VPaIγ.
Candidate effectors (including divergent vopV and vopZ homologs) are colored red. Arrows
designate open reading frames. Grey bars indicate the percent similarity between homologs. tdh3VPaIγ representative strain MAVP-Q (MF066646). tdh5-VPaIγ representative strain CT4291
(SRX7416425).
VPaIγ effector orthologs contain amino acid variation
Next, we compared the effectors’ amino acid composition to examine whether the
nucleotide divergence between VPaIγ effectors led to nonsynonymous mutations that could impact
effector function. Alignments of effectors used to construct the ML trees in Figure 3.4, were
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translated and color-coded by amino acid grouping to aid in the visualization of differences (Figure
3.6)

269

. After collapsing the conserved sites, the effectors contained unequal percentages of

variable amino acid sites. The percentage of variable amino acid sites in ORF32, ORF35, ORF76,
and ORF81 was 15.9%, 4.4%, 16.6%, and 10.8% respectively. Due to the deletions and/or
duplications and the repetitive nature of the ORF34 sequence that makes alignment difficult, the
percentage of variable amino acid sites was not calculated for ORF34.
A direct comparison of the effectors’ amino acid composition from the tdh3-VPaIγ and
tdh5-VPaIγ revealed three of the novel effectors, ORFs 32/76/81, differ in amino acid composition
in their N-terminal region. This region of T3SS effectors contain structural patterns that include a
targeting signal in the first ~15-30 amino acid residues, an optional chaperone binding domain in
the following ~50-150 amino acids, and the remaining protein generally consists of effector
binding domains. ORF76 has a dramatic change in the N-terminal region, with a cysteine at
position 15 in tdh5-VPaIγ and a bulky tyrosine in tdh3-VPaIγ. This results not only in different
size residues but also potentially alters the formation of a disulfide bridge. There is no recognizable
universal secretion signal of T3SS effectors, and thus advanced machine learning approaches are
necessary to predict these effectors 202,207,208,270–272. Despite the amino acid alterations in protein’s
secretion signal region, we cannot determine if these changes alter secretion. The amino acid
composition of the chaperone binding and effector domain regions of all five effectors differed
between tdh3-VPaIγ and tdh5-VPaIγ. Notably, ORF34 orthologs from tdh3-VPaIγ and tdh5-VPaIγ
contained two amino acid differences in the effector domain region, by lineage, that could alter
each protein structure. The two orthologs have amino acid residues, either isoleucine or a tyrosine,
that vary in size at position 1348. At position 1412 in the protein, the two orthologs have either a
negatively charged glutamic acid residue or a positively charged lysine residue. These dramatic
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changes suggest that protein structure would change, thus potentially altering function. However,
since there is no data on the function of these effectors, we cannot predict how these changes
actually alter the functionality of this protein.

83

ORF32
Island
VPaIß
VPaIß
tdh 5-VPaIγ
tdh 5-VPaIγ
tdh 6-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ

ST
1127
631 CI
674
34/324
43
636
36
631 CII

Strain
MAVP-25
MAVP-R
CT4291
CTVP19C
MAVP-71
MAVP-50
MAVP-26
MAVP-Q

1
?
M
M
M
M
M
M
M

5
L
L
L
L
I
L
L
L

6
T
T
T
T
N
T
T
T

11 12
Q N
Q N
Q H
Q H
K H
Q H
Q H
Q H

13
F
F
N
N
N
N
N
N

14
I
I
I
I
T
T
T
T

21
D
D
N
N
N
N
N
N

23 24 25 36 40 41
G D N S K P
G D N S K P
S E S S N T
S E S S N T
S E N N K T
S E N N K T
S E N N K T
S E N N K T

53
L
L
F
F
F
F
F
F

54
G
G
A
A
G
G
G
G

65
L
V
L
L
L
L
L
L

77
A
A
T
T
T
T
T
T

82
D
D
N
N
N
N
N
N

ST
1127
631 CI
308
43
674
34/324
636
36
631 CII

Strain
MAVP-25
MAVP-R
MAVP-67
MAVP-71
CT4291
CTVP19C
MAVP-50
MAVP-26
MAVP-Q

12
F
F
L
F
L
L
L
L
L

24
F
I
F
F
F
F
F
F
F

31
I
V
V
V
V
I
I
I

32 33
- P E
P E
P E
P E
P E
P E
P E
P E

34
V
V
?
V
V
V
?
?
?

35
P
P
P
P
P
-

36
E
E
E
E
E
-

37 38 39
? - ? - - - ? - ? - V P E
- - - - - - -

ST
1127
631 CI
674
34/324
308
43
636
36
631 CII

Strain
MAVP-25
MAVP-R
CT4291
CTVP19C
MAVP-67
MAVP-71
MAVP-50
MAVP-26
MAVP-Q

11
P
H
P
P
P
P
P
P
P

18
Q
Q
P
P
P
P
P
P
P

Amino Acid Position
60 91 119 129 218 226 237
L E A G N S
T
L E A G N A S
L E S D N S
S
L E S D N S
S
F E A D S
S
S
L E V G N S
S
F Q A D N S
S
F Q A D N S
S
F Q A D N S
S

ST
1127
631 CI
674
34/324
308
43
636
36
631 CII

Strain
MAVP-25
MAVP-R
CT4291
CTVP19C
MAVP-67
MAVP-71
MAVP-50
MAVP-26
MAVP-Q

8
P
P
S
S
P
P
P
P
P

10
Q
Q
N
N
Q
Q
Q
Q
Q

12
S
S
G
G
S
S
S
S
S

15 16
Y S
Y S
C N
C N
Y S
Y S
Y S
Y S
Y S

17
G
G
H
H
G
G
G
G
G

18
K
K
K
K
Q
K
K
K
K

20
H
H
N
N
H
H
H
H
H

22 24 25 29 32
E A A R S
E A A R S
E T T I S
E T T I S
E A A R F
A A A R F
A A A R F
A A A R F
A A A R F

ST
1127
631 CI
674
34/324
308
43
636
36
631 CII

Strain
MAVP-25
MAVP-R
CT4291
CTVP19C
MAVP-67
MAVP-71
MAVP-50
MAVP-26
MAVP-Q

6
K
K
Q
Q
Q
Q
Q
Q
Q

7
K
K
K
K
K
K
R
R
R

13
N
N
N
N
Y
Y
Y
Y
Y

33
L
L
I
I
L
L
L
L
L

44
N
N
S
S
N
N
N
N
N

51
I
V
I
I
I
I
I
I
I

53
K
T
K
K
K
K
K
K
K

Amino Acid Position
54 59 69 74 88 105 128 138 151 163 171
L S S V I L S
T A N N
L L S A I L S
T A N N
F L I V T H T T T T D
F L I V T H T T T T D
L L S V T H T T A T D
L L S V T H T T A T D
L L S V T H T A A T D
L L S V T H T A A T D
L L S V T H T A A T D

97
R
R
S
S
R
R
R
R

99
H
H
N
N
N
N
N
N

101
E
E
D
D
D
D
D
D

Amino Acid Position
103 117 128 152
K
E
E
G
K
E
K
G
N
D
K
G
N
D
K
G
N
E
K
G
K
E
K
K
E
K
K
E
K
-

153 160 165 166
V
D F
E
V
D V E
V
E V K
V
E V K
V
E V K
D V E
D V E
D V E

174 197 198 209 218 222 223 224
N L V N A K E K
K P V N T K E K
K P A N A K G K
K P A N A K G K
K P A N A R G R
K P V S A K E K
K P V S A K E K
K P V S A K E K

232 242 243 264 271 279
N V L T T T
N V L T T T
S
I
S
I
A D
S
I
S
I
A D
S
I
S
I
A D
N V L T T T
N V L T T T
N V L T T T

284 290
M *
M *
L
?
L
?
L
?
M *
M *
M *

ORF34
Island
VPaIß
VPaIß
tdh 5-VPaIγ
tdh 5-VPaIγ
tdh 6-VPaIγ
tdh 6-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ

40
?
?
?
?
?
V
?
?
?

Amino Acid Position
89 157 348 588 655 730 863 889 915 1047 1166 1311 1348 1382 1412
S V R T S G V V
I
L
I
S
I
F
E
S V R T S G V L
I
L
I
S
T
Y
E
A V R R G G M V
I
P
T
N
I
Y
E
A I
R R G S M V
I
P
T
S
I
Y
E
A V R R D G M V
I
P
T
N
I
Y
E
A V R R D G M V
I
P
T
N
I
Y
E
A V R R G G M V V
P
T
S
T
Y
K
A V R R G D M V V
P
T
S
T
Y
K
A V K R G G M V V
P
T
S
T
Y
K

ORF 35
Island
VPaIß
VPaIß
tdh 5-VPaIγ
tdh 5-VPaIγ
tdh 6-VPaIγ
tdh 6-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ
ORF 76
Island
VPaIß
VPaIß
tdh 5-VPaIγ
tdh 5-VPaIγ
tdh 6-VPaIγ
tdh 6-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ

33
H
H
H
H
N
N
N
N
N

38
K
R
K
K
K
K
K
K
K

45
K
K
Q
Q
T
T
T
T
T

54
D
D
G
G
D
D
D
D
D

56
D
D
N
N
N
N
N
N
N

Amino Acid Position
65 90 105 137 144
H L G
D
S
H L G
D
S
H V G
E
I
H V G
E
I
H L G
D
S
H L E
D
S
Y L G
D
S
Y L G
D
S
Y L G
D
S

146
A
A
S
S
A
A
A
A
A

152
G
G
R
R
G
G
G
G
G

159
I
I
I
I
L
L
L
L
L

266
V
V
A
A
V
V
V
V
V

288
S
S
S
S
N
N
N
N
N

331
V
V
L
L
V
V
V
V
V

160 164 165 169 170 177 190 194 198 199 217 227
A
K M A A V A K A M T E
A
K M A A V A K A M T E
A
E
I
A S
I
E N V L M K
A
E
I
A S
I
E N V L M K
T
K M T S
I
A K A M T K
T
K M A S
I
A K A M T K
T
K M A S
I
A K A M T K
T
K M A S
I
A K A M T K
T
K M A S
I
A K A M T K

ORF81
Island
VPaIß
VPaIß
tdh 5-VPaIγ
tdh 5-VPaIγ
tdh 6-VPaIγ
tdh 6-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ
tdh 3-VPaIγ

43
K
R
K
K
K
K
K
K
K

203 227 244
E D
T
E D
T
E G
A
E G
A
E D
T
E D
T
K D
T
K D
T
K D
T

251
T
T
M
M
T
T
T
T
T

Figure 3.6: Variable amino acid composition associated with VPaIγ lineage. tdh5-VPaIγ strains include CT4291=ST674 and
CTVP19C=ST34/324, VPaIβ strains include MAVP25=ST1127, MAVP-R=ST631 clade I, tdh6/7-VPaIγ strains include
MAVP67=ST308 and MAVP71=ST43, and tdh3-VPaIγ MAVP-Q=ST631 clade II, MAVP-26=ST36, MAVP-50=ST636.
Amino Acid coloring scheme: blue = positively charged, red = negatively charged, green = polar uncharged, light yellow =
hydrophobic, yellow = proline/tyrosine, orange = cysteine, purple = glycine.

When comparing just the effector amino acid composition of tdh3-VPaIγ and tdh5-VPaIγ
effector orthologs, ORF32 and ORF76 have the lowest percent amino acid similarity at 94.8% and
89.9%, respectively. In contrast, ORF34 and ORF35 orthologs are more highly conserved, with
amino acid identity at 99.3% and 99.2% (Table 3.2).

Table 3.2: VPaIγ gene variation. BLASTx percent sequence identity between tdh5-VPaIγ strain
CT4291 and tdh3-VPaIγ strain MAVP-Q.
Gene
Percent Sequence Identity
ORF32
94.8
ORF34
99.2
ORF35
99.3
ORF76
89.9
ORF81
97.4
VopA
91.1
VopC
87.9
VopL
94.3
VopV analog
96.2 (146 partial hits)
VopZ analog
95.5
tdh5-VPaIγ-harboring V. parahaemolyticus require T3SS2 effectors for survival against
amoeba predation.
Since tdh3-VPaIγ and tdh5-VPaIγ confer reciprocal patterns of clinical and environmental
prevalence, we next examined whether T3SS2 secretion of effectors promote environmental
fitness. We hypothesize that differences in the effectors could have resulted from environmental
selection of predation, and in so doing deter protist grazing. We analyzed the growth of V.
parahaemolyticus strains in the presence of the amoeba predator Acanthamoeba castellanii 273 to
test whether the T3SS toxins secreted by tdh3-VPaIγ and tdh5-VPaIγ deters protist grazing (Figure
3.7). Loss of T3SS1 and T3SS2 effectors secretion did not alter survival under grazing pressure
for V. parahaemolyticus harboring tdh3-VPaIγ. Conversely, loss of the T3SS effector secretion in
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V. parahaemolyticus strains harboring tdh5-VPaIγ did impair survival under grazing pressure from
A. castellanii.

wt
ΔvscN1
ΔvscN1 ΔvscN2
wt
ΔvscN1
ΔvscN1 ΔvscN2

Figure 3.7: tdh5-VPaIγ T3SS effectors protect against protozoan predation. 10-fold dilutions
of V. parahaemolyticus were co-cultured with amoeba predator A. castellanii and grown on LB
agar.
T3SS effectors from tdh3-VPaIγ promote killing of Galleria mellonella
Next, we used the well-established virulence model, Galleria mellonella, to assess the
relative contribution of T3SS2 effectors from tdh3-VPaIγ and tdh5-VPaIγ to pathogenesis. Larvae
of the greater wax moth G. mellonella have been used as an infection model since 1987 274 because
they provide a useful insight into the pathogenesis of a wide range of microbial infections,
including fungal and bacterial pathogens

275

. Similar to mammals, insects such as G. mellonella

possess a complex innate immune system that can provide relevant information towards the
mammalian infection process

275

. In this study, G. mellonella were challenged with V.

parahaemolyticus strains with and without functional T3SSs to assess the pathogenicity
contributed by each system (Figure 3.8).
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Post-infection, G. mellonella were assigned a Health Index score as reported in Loh et al.
276,277

based on survival, activity, cocoon formation, and melanization. G. mellonella had similar

health index scores post-infection with wild type tdh3-VPaIγ and tdh5-VPaIγ harboring strains.
Elimination of secretion by the ancestral and conserved T3SS1 (∆vscN1) ameliorated larvae
damage by an environmentally prevalent tdh5-VPaIγ strain (ST674 strain, CT4291) to similar
levels of PBS buffer injection control. Although elimination of T3SS1 (∆vscN1) qualitatively
ameliorated larval damage by a clinically prevalent tdh3-VPaIγ strain (ST631 strain MAVP-Q), it
did not do so significantly, likely due to substantial intra-animal variability in response to injection
with the wild type. Additionally, eliminating the T3SS2 (∆vscN2) system’s function from the
T3SS1 mutants (a T3SS1/T3SS2 (∆vscN1/∆vscN2) double mutant) did not significantly increase
larval health by either strain compared to the single T3SS1 (∆vscN1) mutant. But, importantly,
level or larval damage by the tdh3-VPaIγ-harboring T3SS1/T3SS2 (∆vscN1/∆vscN2) double
mutant was significantly different from levels of damage achieved by wild type bacteria.
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ΔvscN1
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Figure 3.8: V. parahaemolyticus kills Galleria mellonella using a T3SS. Health index score of
G. mellonella following infection with V. parahaemolyticus strains harboring tdh3-VPaIγ and
tdh5-VPaIγ, and corresponding TTSS1 and T3SS2 mutants after infection for 24 hours. A higher
health index rating indicates better health of G. mellonella post-infection. * = p <0.05 each pair
Student’s t for pair-wise comparisons.
VPaIγ effectors confer differential toxicity towards eukaryotic cells
To evaluate each effector’s impact on conserved eukaryotic processes, we used a
heterologous expression system for T3SS effector toxicity in Saccharomyces cerevisiae. The
proteins were expressed under the control of a galactose-inducible promoter to determine if their
toxicity impaired yeast growth. When yeasts expressed ORF34 from tdh3-VPaIγ or tdh5-VPaIγ
under inducing conditions, they grew nearly as well as they did when grown under the same
conditions with control empty vector, suggesting neither ortholog was individually toxic (Figure
3.9A). In contrast, both tdh3-VPaIγ and tdh5-VPaIγ ORF35 orthologs impaired yeast growth.
Additionally, tdh3-VPaIγ and tdh5-VPaIγ effector orthologs for ORF32, ORF76, and ORF81
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impaired growth to differing degrees, based on visual assessment. Yeast harboring ORF32 from
tdh3-VPaIγ grew the same under both inducing and non-inducing conditions. ORF32 from tdh5VPaIγ expression reduced yeast growth substantially. While both ORF76 and ORF81 from tdh3VPaIγ reduced yeast growth more than the orthologous ORFs from tdh5-VPaIγ, only ORF81induced growth reduction in yeast was significant (Figure 3.9B). In congruence with previous
studies 124, known effectors VopA was toxic to yeast, and VopC was not.
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A.

B.

ORF76

ORF81

Figure 3.9: Orthologous effectors from tdh3-VPaIγ and tdh5-VPaIγ lineages exhibit differences in toxicity towards yeast.
A) Four-fold dilutions of yeast transformed with pYES2.1:toxin (from tdh3-VPaIγ of ST631 clade II and tdh5-VPaIγ ST674)
were grown under non-inducing (glucose) and inducing (galactose) conditions. B) Toxicity toward yeast was measured by
growth on agar plates. CFU/mL was estimated from colony growth under non-inducing and inducing conditions and reported as
a reduction in growth upon induction. * = p<0.001 Tukey Kramer HSD in pairwise comparisons.

T3SS2 effectors from tdh3-VPaIγ and tdh5-VPaIγ differ in the cytotoxicity of human colon
cells.
Next, to compare the degree to which tdh3-VPaIγ and tdh5-VPaIγ effector orthologs were
involved in T3SS2 dependent cytotoxicity against human colon cells, we co-cultured effector
deletion mutants of V. parahaemolyticus strains with cultured Caco-2 colorectal tumor cells. The
strain’s cytotoxicity was evaluated by the release of cytosolic lactate dehydrogenase (LDH) from
Caco-2 cells (Figure 3.10). Because the effectors secreted by the ancestral T3SS1 of V.
parahaemolyticus do not contribute to enterotoxicity during infection but are cytotoxic to cultured
human colon cells, we eliminated the secretion of T3SS1 effectors by deleting the T3SS1 ATPase
(vscN1) prior to generating individual T3SS2 effector knockouts. Therefore, all strains other than
the wild type carry a ΔvscN1 mutation.
V. parahaemolyticus strains harboring T3SS1 were cytotoxic towards Caco-2 cells,
regardless of which VPaI they carried (tdh3-VPaIγ or tdh5-VPaIγ) with tdh5-VPaIγ strain causing
slightly less cell damage. This similar cytotoxicity is likely due to the presence of the ancestral
T3SS1. When this system is removed, the strain harboring tdh3-VPaIγ was more cytotoxic than
the strain harboring tdh5-VPaIγ. Since Caco-2 cytotoxicity assays are a proxy for V.
parahaemolyticus virulence, this result agrees with our expectation that the more clinically
prevalent strains harboring tdh3-VPaIγ are more toxic than strains harboring tdh5-VPaIγ.
Next, we evaluated the contribution of T3SS2 and its effectors to cytotoxicity by T3SS2.
Deleting the accessory T3SSs ATPases (ΔvscN2) in tdh3-VPaIγ and tdh5-VPaIγ harboring strains
reduced cytotoxicity towards Caco-2 cells to similar levels. Deleting ORF32 from tdh3-VPaIγ did
not reduce the cytotoxicity of V. parahaemolyticus, whereas knocking out ORF32 from tdh5VPaIγ dramatically reduced its cytotoxicity. ORFs 34 and 35 are likely co-transcribed and thus
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were deleted together, and designated ORF34-35. The ΔORF34-35 mutation reduced cytotoxicity
of the tdh3-VPaIγ significantly more than the same mutation in the tdh5-VPaIγ strain. ΔORF76
and ΔORF81 homolog deletions also followed a similar pattern of cytotoxicity as ΔORF34-5, but
only the ΔORF81 derivatives significantly differed from each other. The analogs to the VPaIα
primary effectors VopV and VopZ were also deleted in VPaIγ strains and assessed for cytotoxicity.
Though divergent, the tdh3-VPaIγ VopV and VopZ homologs are cytotoxic.

ΔORF34-35
ΔvscN1

ΔvopZ
ΔvscN1

Figure 3.10. Reduced cytotoxicity towards Caco-2 cells mirrors the difference in toxicity
towards yeast. The human colorectal cancer cell line, Caco-2 cells, were co-incubated with V.
parahaemolyticus strains defective in T3SS1 and harboring indicated ORF deletions. We predict
ORFs 34 and 35 are co-transcribed and thus deleted both simultaneously. Percent cytotoxicity,
estimated by the quantity of lactate dehydrogenase (LDH) in the well after co-culture, was
calculated by the following equation: [optical density at 490 nm (OD490) of experimental release OD490 of spontaneous release]/(OD490 of maximum release - OD490 of spontaneous release)*100%.
Spontaneous release is the amount of LDH released from the cytoplasm of uninfected cells. The
maximum release is the total amount of LDH released after the complete lysis of uninfected cells.
* = p <0.001 Tukey Kramer HSD for pair-wise comparisons. Data represents the mean ± standard
deviation from one experiment using five individual bacterial colonies per strain, performed in
triplicate. The experiment was repeated twice with similar results
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Discussion
The continuous global spread of V. parahaemolyticus has led to population mixing and
horizontal gene transfer of VPaIs 11,22,26,48,197. The pathogenicity island’s additional genetic content
expands the flexible gene pool and may enhance fitness under specific environmental conditions
278

. For example, toxins secreted by the T3SS2 on VPaIα enhance V. parahaemolyticus persistence

while in the presence of bacterivorous protists 273 and enable growth and invasion in mammalian
gastrointestinal tract 139,141,147. Here we provide evidence that strains with different VPaIγ lineages
recently spread into the North Atlantic population

11,22,197

contain evolutionary divergent toxins

that may provide a fitness benefit. The blocks of homoplasy in the VPaIγ lineages likely indicate
recombination in each of the geographic populations. This is exemplified by tdh6-VPaIγs
containing different recombination regions that correlate with the population they evolved with.
The Pacific-evolving tdh7-VPaIγ has blocks of recombination similar to that of the fellow Pacificevolving tdh3-VPaIγ clade, and the Gulf of Mexico-evolving tdh7-VPaIγ has some blocks of
recombination similar to that of the fellow Gulf of Mexico-evolving tdh5-VPaIγ clade. This
recombination pattern indicates that the surrounding population is a major contributor to the
content of these VPaIs. This pattern could have arisen by an ancestor VPaIγ-harboring strain that
began evolving with their local areas during global spread. Continued analysis of these populations
that recently relocated to the Northwest Atlantic will demonstrate local population’s role in
shaping the evolution of these islands.
In the North Atlantic, tdh3-VPaIγ containing strains are clinically prevalent and
environmentally infrequent, while the reciprocal pattern occurs with tdh5-VPaIγ containing strains
11

. This reciprocal clinical/environmental relationship between tdh3-VPaIγ and tdh5-VPaIγ

containing strains suggests that variation in gene content between the islands could promote
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infection or environmental success, respectively. Since geographic signatures in the patterns of
recombination differ between the Pacific and the Gulf of Mexico/Atlantic evolving populations,
we evaluated whether the toxins from the tdh3-VPaIγ and tdh5-VPaIγ lineages originating out of
these regions contribute to the VPaIs’ reciprocal environmental and clinical prevalence in the
North Atlantic. We assessed the contribution of the tdh3-VPaIγ and tdh5-VPaIγ towards clinical
and environmental success using three functional models systems: G. mellonella infection

279

,

human colon cell culture cytotoxicity 9, and A. castellanii predation 280.
During infection, V. parahaemolyticus faces defenses from the human innate immune
system. To assess whether the effectors secreted by the accessory T3SS on VPaIγ promote
successful invasion, we challenged G. mellonella with V. parahaemolyticus. The G. mellonella
infection model has been used to assess bacterial virulence against innate immune defenses for
many gram-negative pathogens
Legionella pneumophila

283

277

such as Pseudomonas aeruginosa

, and Klebsiella pneumonia

284

281

, Escherichia coli

282

,

. The insect innate immune system is

complex and mirrors responses seen in mammals such as cellular response, humoral response, and
antibacterial peptide production

285,286

. Our results suggest that the T3SS effectors from tdh3-

VPaIγ contribute towards the successful invasion of V. parahaemolyticus by overcoming innate
immune system defenses 275,277. This response displays the virulence fitness benefit conferred by
the presence of VPaIγ in V. parahaemolyticus.
V. parahaemolyticus colonizes primarily the distal small intestine during infection, where
it forms microcolonies and induces substantial epithelial damage

125,135,137,138

. In this study the

Caco-2 were representative of differentiated enterocytes that occur in the small intestine
previously shown as an effective proxy for evaluating gastric pathogen virulence

124,141,165

245

,

. We

identified which T3SS effectors promoted V. parahaemolyticus virulence, without other
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confounding variables such as mucus, microbiota, and the innate immune system 245. Co-culture
of Caco-2 cells with tdh3-VPaIγ and tdh5-VPaIγ harboring strains of V. parahaemolyticus indicate
that the tdh3-VPaIγ T3SS2 effectors are greater contributors to the cytotoxicity of these human
colon cells than those from tdh5-VPaIγ.
Like other opportunistic pathogens such as P. aeruginosa 287, V. parahaemolyticus evolves
in the environment where toxin secretion is an important defense tactic against protozoan predation
263,288

. Protozoan predators are considered the “training grounds” for bacterial pathogens, allowing

refinement of defense tactics, which are coincidentally beneficial to pathogenesis in humans
263,289,290

. V. parahaemolyticus is a member of the marine community 33,291,292 and thus commonly

interacts with protozoan predators

273,293

. The T3SS effectors on VPaIα promote survival of V.

parahaemolyticus against diverse protist predators 273, similarly to the protective effects shown by
T3SS effectors from tdh5-VPaIγ against the predation pressure from A. castellanii. Intriguingly,
the tdh3-VPaIγ-harboring strain was not affected by A. castellanii predation. To be a significant
human pathogen, V. parahaemolyticus needs to survive in the environment and grow to high
enough concentrations to be ingested by humans, perhaps these V. parahaemolyticus lineages have
a mechanism outside of the VPaIγ that allows for increased environmental survival.
Our findings suggest that the difference between the clinical prevalence of tdh3-VPaIγ and
tdh5-VPaIγ may in part be attributed to their T3SS effectors. To determine which effectors may
underlie potential differences in virulence, we utilized a bioinformatic and experimental approach
to compare the effectors in these islands and assess their virulence contribution. Three of the five
effectors, ORFs 34/35/81 were not in blocks of homoplasy, most likely indicating that they were
either not in recombining regions or convergence was not occurring on these loci. It appears that
ORF35 could be undergoing convergence. Convergence at this loci could be supported since
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ORF35 had the shortest branch lengths of all ortholog phylogenies and had the lowest percentage
of variable amino acid content between all orthologs examined. The most divergent lineages of
ORF35, tdh3-VPaIγ and tdh5-VPaIγ, still maintain 99.336% sequence identity at the nucleotide
level, suggesting maintenance at this locus is important, likely indicting positive selection 294. Two
of the five toxins, ORF76 and the first half of ORF32, were in blocks of recombination. The
presence of ORF76 in this region is indicative of recombination at this loci within the tdh5-VPaIγ
clade. ORF76 orthologs contain the highest percentage of variable amino acid content of all five
T3SS effectors, and they have the most substantial divergence in the ortholog phylogeny between
tdh3-VPaIγ and tdh5-VPaIγ as indicated by the longest branch lengths. ORF32 is in a region of
recombination within all four VPaIγ lineages, and this recombination shines through in its high
percentage of variable amino acid content between the ORF32 orthologs. The ortholog
phylogenies of all five toxins show substantial divergence between the tdh3-VPaIγ and tdh5-VPaIγ
toxin sequences. The modifications in toxins may contribute to their effectiveness in conferring
pathogenesis or environmental fitness.
In comparing just effector amino acid composition from tdh3-VPaIγ and tdh5-VPaIγ
orthologs, there are major amino acid changes between the two islands in both the chaperone
binding and effector domain regions of all orthologs, though the way in which these novel effectors
function is not yet known. Even so, these changes could alter virulence if the chaperone cannot
bind as effectively, or the functional domains are not working as well. One of the most interesting
differences is two amino acid changes in the M60-like domain of ORF34. This domain typically
possesses mucinase activity, which could be beneficial in breaking down the protective mucin
layer produced by enterocytes to allow for better bacterial adhesion

224,227,295,296

. This domain is

conserved in both pathogenic and commensal bacteria in Proteobacteria, Firmicutes, and

96

Bacteroidetes 224,295. For example, the Enterotoxigenic Escherichia coli (ETEC) effector Yghl, also
contains an M60-like protease domain, which degrades mucus proteins in mouse small intestine
epithelium

227,296

. The two changes that could affect the protein structure are a size change at

position 1348 from isoleucine to tyrosine, and a side chain charge switch at position 1412 from a
negatively charged glutamic acid to a positively charged lysine. Three of the predicted effectors,
ORFs 32/76/81, have a possible amino acid change in their N-terminal secretion signal region.
Changes in sequence here could mistarget an effector, causing less secretion, and thus less
biological effect on its target. ORF76 has a dramatic change in the N-terminal region, with a
cysteine at position 15 in tdh5-VPaIγ and a bulky tyrosine in tdh3-VPaIγ. There is a size difference
between these residues, and the possible formation of a disulfide bridge can dramatically alter the
protein structure. Nonsynonymous substitutions can affect numerous protein features such as
expression, folding, and binding affinity, which in turn may influence fitness 297–299. Amino acid
changes seen in these toxins may in part influence the clinical prevalence of strains harboring these
VPaIγs.
Finally, to begin efforts to elucidate each effector’s function, we utilized growth inhibition
phenotyping of yeast expressing the toxins from tdh3-VPaIγ and tdh5-VPaIγ. This yeast growth
inhibition model assesses if a protein negatively affects conserved eukaryotic processes such as
those associated with the cytoskeleton, Rho G and MAPK signaling pathways, apoptosis, and
vesicle trafficking

233,235

. Of the surveyed effectors, only ORF32 and ORF81 homologs varied

significantly in their toxicity towards yeast, mirroring the results from human colon cell infection.
The tdh5-VPaIγ ORF32 was significantly more toxic towards yeast than its homolog from tdh3VPaIγ. Since V. parahaemolyticus evolves in the environment, we hypothesize that the ORF32
ortholog in tdh5-VPaIγ has best evolved for survival against eukaryotic predators in the

97

environment, and Caco-2 cells happen to be susceptible as well. Perhaps ORF32 is the T3SS
effector from tdh5-VPaIγ that promoted survival under grazing pressure from A. castellanii. Our
results could follow the coincidental evolution hypothesis, which suggests that bacterial virulence
factors arise as a protective trait due to the selective pressure of bacterial-protozoan interactions,
and their virulence in humans is an added benefit 263,300. T3SS effectors on VPaIα have shown to
promote survival in the presence of predatory protists

273

. In the yeast model, both ORF34

homologs had almost identical levels of minor growth reduction, and both ORF35 homologs both
killed yeast equally well. When knocked out together, their combined effect truly parses out the
difference between tdh3-VPaIγ and tdh5-VPaIγ homologs. The tdh3-VPaIγ ΔORF34-35 strain
showed significantly more reduction in cytotoxicity than tdh5-VPaIγ ΔORF34-35, indicating that
the structural differences between these two genes may affect infection success. ORF76 and
ORF81 from tdh3-VPaIγ both might contribute to this island’s clinical prevalence since they are
more toxic to yeast and are more cytotoxic to human colon cells than their tdh5-VPaIγ homologs.
Even though further studies are needed to assess each effector’s contribution to gastric infection
138,139,301

, we can see preliminary patterns of toxicity associated with prevalence.

All four VPaIγ lineages contain recombination patterns indicative of population-based
evolution. Our study infers that the T3SS effector variation between tdh3-VPaIγ and tdh5-VPaIγ
could in part contribute to the clinical prevalence of strains harboring tdh3-VPaIγ and
environmental prevalence of strains harboring tdh5-VPaIγ. However further studies are needed to
evaluate the impact these effectors have on V. parahaemolyticus fitness. Based on our preliminary
results, we believe that the variation in ORFs 34/35, ORF76, and ORF81 between tdh3-VPaIγ and
tdh5-VPaIγ orthologs could contribute to the tdh3-VPaIγ clinical prevalence. With all four VPaIγ
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lineages now present and mixing in the North Atlantic, it will be interesting to see how these
islands change over the next decade.
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Materials and Methods
Bacterial, Yeast, and Protist Strains and Culture Conditions
The bacterial strains and plasmids used in this study are described in Table 2.2 and Table 2.3,
respectively. V. parahaemolyticus was routinely grown at 37°C in Luria-Bertani medium
supplemented with 2% NaCl (LBS)

251

or in defined minimal media

252

supplemented with

0.0058% K2HPO4, 0.1% NH4Cl, 0.01mM FeSO4, 0.1 mM Tris pH 7.4, 0.6% glycerol, 1x Artificial
Sea Water, 0.625µg/mL chloramphenicol, and tap water for trace minerals for transformation. E.
coli strains were grown at 37°C in Luria-Bertani medium (LB) as previously described

251

.

Antibiotics were supplemented for selection of mutations and plasmids at the following
concentrations for V. parahaemolyticus: 12 µg/ml gentamicin (Gen), 2.5 µg/ml chloramphenicol
(Chl), and 5 µg/ml erythromycin (Erm) and at the following concentrations for E. coli: 50 µg/ml
kanamycin (Kan), 100 µg/ml ampicillin (Amp), and 25 µg/ml chloramphenicol (Chl).
S. cerevisiae BY4742 (obtained from Clyde Denis,

253

) was maintained in Yeast extract (1%)-

peptone (2%)-and dextrose (2%) medium (YPD)253. Yeast were grown on Synthetic Complete
Minimal Media (SC-MM) made with Yeast Synthetic Drop-out Medium Supplements without
uracil (Sigma-Aldrich), supplemented with glucose at 2% once transformed with pYES2.1/V5His-TOPO®. S. cerevisiae was grown at 28°C.
A. castellanii was routinely maintained in proteose peptone, yeast extract, and glucose (PYG)
medium (ATCC 712 PYG). A. castellanii were maintained by subculturing 4.2% culture into fresh
PYG every 10-14 days.
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Bioinformatic Analyses
To investigate the phylogeny of VPaI elements, the sequences of pathogenicity islands were
extracted from assembled draft genomes using as a reference the island sequences of MAVP-Q
(MF066646), allowing the identification of complementary regions in draft genomes using
Mauve302. Coordinates were recorded for the pathogenicity island region from the contigs of each
genome which were then manually extracted. The sequences from each VPaI were then aligned
by MAFFT303. The aligned sequences file was then analyzed and an ML tree constructed as
described for tdh genes. Subsequently, phylogeny and recombination among islands from select
genomes was also conducted using the aligned FASTA file in Gubbins68 with the default setting.
The identities of genes within recombining regions were determined based on the coordinates of
the reference sequence. To determine the phylogeny of effector orthologs, all ortholog gene
sequences were extracted from both draft and closed genomes using BLASTn254. Orthologs
identified using BLASTx254 with 99% sequence identity and ranging from 61.28% -98.49% query
coverage were used as outgroups. Alignments were performed by MAFFT303 and maximumlikelihood (ML) tree was constructed using RAxML 304. Phylogenetic trees were viewed and colorcoded in Interactive Tree Of Life (iTOL) 305. Alignments were viewed in MEGA269 to visualize
amino acid variability. Gene content and order of the VPaI elements in MAVP-Q and CT4291
were illustrated by Easyfig 306.

Molecular genetic methodologies and plasmid construction
PCR SOE and cloning
Primers for generating constructs used in marker exchange mutagenesis were designed as
recommended 255. Oligonucleotide primers were synthesized by © Integrated DNA Technologies
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(Coralville, IA). PCR cycling conditions were optimized using AccuStart II PCR SuperMix
(Quantabio, Beverly, MA). Genomic DNA from V. parahaemolyticus strain MAVP-Q, a ST631
clade II member containing VPaIγ, from VPaIγ, and strain MAVP-C, a pandemic ST3 strain
containing VPaIα,was used as a template to generate amplicons upstream and downstream of the
gene of interest, whereas amplicons of the antibiotic cassettes were generated using plasmids
pBD4 and pEVS170 (Table 2.4). Genomic DNA was prepared by organic DNA extraction

256

.

Oligonucleotide primers for gene knockouts were designed to contain at least 400bp regions
flanking the gene of interest to enable efficient recombination (Table 2.3). Oligonucleotide primers
for the antibiotic cassette to replace the gene of interest were designed to contain the native
antibiotic resistance cassette promoter from the plasmid (Table 2.3). Analysis of the secondary
structure of primers was performed by NetPrimer (©PREMIER Biosoft). Gene knockouts and
antibiotic resistance genes were amplified from target DNA with Phusion® High-Fidelity DNA
Polymerase or Phusion® High-Fidelity PCR Master Mix (©New England Biolabs, Ipswich, MA)
according to ©New England Biolabs Inc. protocol. PCR SOE was performed as described

255

.

PCR SOE product was cloned into pCR2.1TOPO® and transformed into chemically competent E.
coli 10-beta cells (New England Biolabs®, Ipswich, MA) following Invitrogen pCR2.1TOPO®
(Invitrogen K202020) protocol. Plasmid DNA was purified using ©QIAGEN Plasmid Kit protocol
with house-made ©QIAGEN reagents. Confirmation that the constructs contained no PCR
generated errors was determined by sequencing using the Sanger method by ©GENEWIZ LLC
(South Plainfield, NJ, USA).
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Transformation of V. parahaemolyticus
V. parahaemolyticus strains harboring pSEE1 were grown to turbidity in LBS and subsequently a
2% inoculum was used to grow an overnight culture at RT in minimal medium supplemented with
0.2% arabinose. Once cultures reached OD600 > 0.5, 0.5 mL culture was mixed with 2 µg of either
plasmid DNA or ~10 µg of genomic DNA that was sheared by freeze-thaw three times at -20°C,
and incubated at 28°C statically for 30 minutes. 0.5 mL LBS was added to the culture and was
incubated at 37°C for 20-60 minutes. Cells were pelleted and suspended in ~50 µl LBS broth.
Equal volumes of transformant were plated onto three concentrations of antibiotic flanking
estimated optimal concentration (10/12/15 µg/ml gentamycin and 2.5/5/8 µg/ml erythromycin)
and grown at 37°C overnight. Colonies were re-streaked to a plate with a higher concentration of
antibiotic, grown at 37°C, then the colony screened by PCR to identify the presence of the
mutation. Mutants harboring pSEE1 were passaged at a 2% inoculum in LBS twice per day for
two days to lose plasmid.

Acanthamoeba castellanii predation assay
Overnight cultures of V. parahaemolyticus were grown in LBS + 0.04% bile salts was subcultured
1% into fresh LBS + 0.04% bile salts and grown at 37°C until OD600 = ~0.5-1.0. Cultures were
washed once in PBS and adjusted to an OD600 = 0.125. Eight 10-fold dilutions of culture were
performed in 96 well plate. Six-day old A. castellanii culture was pelleted at 500g for 4 minutes
and resuspended in PBS. A. castellanii were adjusted to 1x105 cells/mL, and an equal volume of
A. castellanii was gently mixed with the V. parahaemolyticus dilutions. After 4 minutes of coculture, 10µL dilutions of each well were spotted onto an LB agar plate and grown at room
temperature for two days.
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Galleria mellonella
Overnight cultures of V. parahaemolyticus were subcultured 1% into fresh LBS + 0.04% bile salts
to induce T3SS activity, or with no addition, and grown to mid-log phase. Pelleted cells were
washed with Phosphate’s Buffered Saline (PBS) twice, and the OD600 used to estimate cell
numbers taken and cells diluted appropriately. G. mellonella were separated into treatment groups
and two controls: one no-injection and one injected with PBS. All individuals in the treatment
groups were inoculated with 10ul diluted V. parahaemolyticus in PBS, and their survival and
health were monitored and recorded at 24 hours, 48 hours and 72 hours post-inoculation. The
Colony Forming Units (CFU) were determined by the direct plating method for each inoculum
dose. G. mellonella were scored for survival, activity, cocoon formation and melanization and a
health index score was calculated for each treatment as per Tsai 2016 277.

Toxin expression vector construction
To express putative toxins in yeast, genes were cloned from designated V. parahaemolyticus
strains, cloned into a pYES2.1/V5-His-TOPO® (Invitrogen) vector shuttle plasmid that can be
generated in E. coli, and then expressed in yeast. The forward oligonucleotide primers to amplify
toxins contained a synthetic altered Kozak sequence (FRBS) overlapping the start codon of the
gene of interest as recommended by manufacturer (Invitrogen). The forward primer contained the
native sequence, except for the bolded nucleotides surrounding the underlined start codon
(G/A)NNATGG for optimal expression in yeast. The reverse primer was designed for
amplification near or at the stop codon of the gene of interest. Both primers were designed with a
melting temperature between 63°- 67°C, and within 1°C of each other. Melting temperatures and
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the secondary structure was analyzed by NetPrimer (©PREMIER Biosoft). Oligonucleotide
primers were synthesized by ©Integrated DNA Technologies (Coralville, IA). PCR cycling
conditions were optimized using AccuStart II PCR SuperMix (Quantabio, Beverly, MA). Toxin
genes were amplified with Phusion® High-Fidelity DNA Polymerase or Phusion® High-Fidelity
PCR Master Mix (©New England Biolabs, Ipswich, MA) according to ©New England Biolabs
Inc. protocol. PCR products were cloned into a pYES2.1/V5-His-TOPO vector (See Table 2.4)
and transformed into One-Shot TOP10F’ E. coli ® following pYES2.1 TOPO™ TA Yeast
Expression Kit (Invitrogen) protocol. Plasmid DNA was prepared using ©QIAGEN Plasmid Kit
protocol with house-made ©QIAGEN reagents and absence of errors confirmed by sequencing
and analysis ©GENEWIZ LLC (South Plainfield, NJ, USA).

Yeast Transformation
To generate competent S. cerevisiae, five colonies of S. cerevisiae BY4742 were grown overnight
with shaking at 28°C. Cultures were diluted to an OD600 of 0.4 in 25 ml of YPD medium and
grown an additional three hours at 28° while shaking. S. cerevisiae was washed twice in 1X
LiAc/0.5X TE for a final volume of 1 mL. S. cerevisiae was incubated for 10 minutes at room
temp. 50µL of S. cerevisiae cells were incubated with 10µL of sheared salmon sperm DNA and
1µg of plasmid prep of toxin:pYES2.1/V5-His-TOPO® for 1hr at 30°C. The sample was mixed
with 250µL 40% PEG 3350 and incubated at 30°C for at least 1hr. Samples were heat-shocked for
15min at 42°C, pelleted, and resuspended in 80µL Milli-Q water. Samples were plated on SC-MM
medium containing 2% glucose and incubated for two days at 28°C/30°C.
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Assessment of effector toxicity by heterologous expression in yeast
To assess the effect of each putative toxin on yeast, S. cerevisiae harboring pYES2.1/V5-HisTOPO® containing individual toxins were streaked for isolation onto SC-MM + glucose 2% and
grown for two days at 28°C. Since glucose can mildly repress the GAL1 promoter driving each
toxin gene, individual colonies were streaked onto SC-MM + raffinose 2% and grown for two days
at 28°C. S. cerevisiae grown in raffinose was inoculated into SC-MM + raffinose 2% broth and
grown overnight at 28°C with shaking. Overnight cultures were washed in Milli-Q water, adjusted
to an OD600 of 2.0, and diluted serially four-fold. 10µL of each dilution was spotted onto SC-MM
+ glucose 2% agar plates to assess normal yeast growth and SC-MM + galactose 1%/raffinose 1%
agar plates to assess yeast growth when galactose induces production of each putative toxin and
grown for two days at 28°C.

Yeast Enumeration
To calculate the effect of each toxin on the yeast, CFU/mL was estimated for S. cerevisiae growth
on SC-MM +glucose 2% agar plates (inducing conditions) and SC-MM + galactose 1%/raffinose
1% agar plates (non-inducing conditions). After two days, log reduction in growth was calculated
by the following formula: Log Reduction = log10(CFU/mL S. cerevisiae from SC-MM +glucose
2% agar plates / CFU/mL S. cerevisiae from SC-MM + galactose 1%/raffinose 1% agar plates).
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Cytotoxicity Assay
Eukaryotic cell culture
Caco-2 cells were regularly maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
ATCC®) containing 10% (v/v) Fetal Bovine Serum (FBS, Sigma®) and Corning® AntibioticAntimycotic Solution at 37°C in 5% CO2.

Cytotoxicity measurements
Caco-2 cells at 80% confluency were washed in DMEM without phenol red + 10% FBS and seeded
25µL of cells at 315 cells/µl in 384-well plates and cultured for 48hr at 37°C in 5% CO2 to
confluency. Unmodified V. parahaemolyticus strains were streaked for isolation onto LBS agar,
ΔvscN1:Gen V. parahaemolyticus mutants were streaked for isolation onto LBS + 5 µg/ml Gen,
and ΔvscN1:Gen/Δ(gene of interest):Erm V. parahaemolyticus mutants were streaked for isolation
onto LBS + 5 µg/ml Erm. All V. parahaemolyticus strains were grown at 37°C until robust colony
growth. Five colonies of V. parahaemolyticus were grown overnight in LBS + 0.04% bile salts at
37°C in a roller drum. Cultures were washed twice in PBS and diluted to add 5µL of culture to
48hr Caco-2 cells at an MOI of 10. Three replicates per sample were added to Caco-2 cells. After
6hrs of co-culture, the release of lactate dehydrogenase (LDH) into the medium was quantiﬁed by
using a CytoTox96® non-radioactive cytotoxicity kit (Promega®) according to the manufacturer’s
instructions. To quantify percent cytotoxicity, the LDH release was calculated with the following
equation: [optical density at 490 nm (OD490) of experimental release - OD490 of spontaneous
release]/(OD490 of maximum release - OD490 of spontaneous release)*100%. Spontaneous release
is the amount of LDH released from the cytoplasm of uninfected cells, whereas the maximum
release is the total amount of LDH released after the complete lysis of uninfected cells.
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Statistical Analysis
For G. mellonella killing assay health index score was calculated for each treatment as per Tsai
2016 277, and Student’s t pairwise comparisons performed for each pair. For yeast, CFU/mL was
estimated from colony growth under non-inducing and inducing conditions. Reduction in growth
upon induction was compared across samples with Tukey Kramer HSD in pairwise comparisons.
Data from Caco-2 cytotoxicity assay represents the mean ± standard deviation from one
experiment using five individual bacterial colonies per strain, performed in triplicate. Pairwise
comparison across strains was performed utilizing Tukey Kramer HSD.
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Table 3.3 Strains and plasmids used in this study
Strain or plasmid

Description

E. coli strains
One-Shot
TOP10F’
10-beta cells

Source of Reference
Thermo Fisher®
New England Biolabs®

V. parahaemolyticus strains
MAVP-Q

WT

GCA_002209725.2

TBD

MAVP-Q derivative ΔvscN1:Gen

This study

TBD

MAVP-Q derivative ΔvscN1:Gen ΔvscN2:Erm

This study

TBD

MAVP-Q derivative ΔvscN1:Gen ΔORF32:Erm

This study

TBD

MAVP-Q derivative ΔvscN1:Gen ΔORF34_ORF35:Erm

This study

TBD

MAVP-Q derivative ΔvscN1:Gen ΔORF85:Erm

This study

TBD

MAVP-Q derivative ΔvscN1:Gen ΔORF90:Erm

This study

TBD

MAVP-Q derivative ΔvscN1:Gen ΔvopV:Erm

This study

TBD

MAVP-Q derivative ΔvscN1:Gen ΔvopZ:Erm

This study

CT4287

WT

This study

TBD

CT4287 derivative ΔvscN1:Gen

This study

TBD

CT4287 derivative ΔvscN1:Gen ΔvscN2:Erm

This study

TBD

CT4287 derivative ΔvscN1:Gen ΔORF32:Erm

This study

TBD

CT4287 derivative ΔvscN1:Gen ΔORF34_ORF35:Erm

This study

TBD

CT4287 derivative ΔvscN1:Gen ΔORF85:Erm

This study

TBD

CT4287 derivative ΔvscN1:Gen ΔORF90:Erm

This study

TBD

CT4287 derivative ΔvscN1:Gen ΔvopV:Erm

This study

TBD

CT4287 derivative ΔvscN1:Gen ΔvopZ:Erm

This study

his3-Δ1 leu2-Δ0 ura3-Δ0 lys2-V0

Pearce 1999

S. cerevisiae strains
BY4742
A. castellanii
30234™

ATCC®

G. mellonella
N/A

N/A

Grubco

Plasmids
pSEE1
pBD4

Competency plasmid; ChlR
R

This Study

R

Gm cassette, Erm

Duerkop 2007
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pEVS170

ErmR cassette, ChlR, mini-Tn5-Erm, oriVR6K oriTRP4
KanR

Adin 2008

pCR2.1-TOPO

cloning vector, KanR

Thermo Fisher Scientific

pSEE21
pSEE22
pSEE23
pSEE24
pSEE25
pSEE26

pCR2.1-TOPO:ST674ORF32::Erm ST674 ORF32
knockout, ChlR, ErmR
pCR2.1-TOPO:ST674ORF34.5::Erm ST674
ORF34/ORF35 knockout, ChlR, ErmR
pCR2.1-TOPO:ST674ORF76::Erm ST674 ORF76
knockout, ChlR, ErmR
pCR2.1-TOPO:ST674ORF81::Erm ST674 ORF81
knockout, ChlR, ErmR
pCR2.1-TOPO:ST674ORFVopV::Erm ST674 VopV
knockout, ChlR, ErmR
pCR2.1-TOPO:ST674ORFVopZ::Erm ST674 VopZ
knockout, ChlR, ErmR

This Study
This Study
This Study
This Study
This Study
This Study

pSEE27

pYES2.1-V5-His-TOPO::ST631ORF32

This study

pSEE28

pYES2.1-V5-His-TOPO::ST631ORF34

This study

pSEE29

pYES2.1-V5-His-TOPO::ST631ORF35

This study

pSEE30

pYES2.1-V5-His-TOPO::ST631ORF76

This study

pSEE31

pYES2.1-V5-His-TOPO::ST631ORF81

This study

pSEE32

pYES2.1-V5-His-TOPO::ST631VopA

This study

pSEE33

pYES2.1-V5-His-TOPO::ST631VopC

This study

pSEE34

pYES2.1-V5-His-TOPO::ST674ORF32

This study

pSEE35

pYES2.1-V5-His-TOPO::ST674ORF34

This study

pSEE36

pYES2.1-V5-His-TOPO::ST674ORF35

This study

pSEE37

pYES2.1-V5-His-TOPO::ST674ORF76

This study

pSEE38

pYES2.1-V5-His-TOPO::ST674ORF81

This study

Gen = gentamycin; Erm = erythromycin; Chl = chloramphenicol; Kan = kanamycin
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Table 3.4: Oligonucleotides used in this study.
Primer name

Target Gene

Genetic Knockouts
PrSEE70 674_vscN2_Erm AF

vscN2

PrSEE71 vscN2_Erm AR

vscN2

PrSEE72 vscN2_Erm BF

PrSEE74 vscN2_Erm CF

ErmR
cassette
ErmR
cassette
vscN2

PrSEE75 vscN2_Erm CR

vscN2

PrSEE76 32_Erm AF

ORF32

PrSEE82 674 32_Erm AR

ORF32

PrSEE83 674 32_Erm BF

PrSEE85 674 32_Erm CF

ErmR
cassette
ErmR
cassette
ORF32

PrSEE86 674 32_Erm CR

ORF32

ORF34.5SoAF

ORF34-35

ORF34.5SoAR

ORF34-35

ORF34.5SoBF

ORF34.5SoCF

ErmR
cassette
ErmR
cassette
ORF34-35

ORF34.5SoCR

ORF34-35

PrSEE73 vscN2_Erm BR

PrSEE84 674 32_Erm BR

ORF34.5SoBR

DNA
template

Sequence

CT4291
gDNA
CT4291
gDNA
pEVS170

TGAAATTGGCAAAGCG

pEVS170

AGACAGCCGAACGTACTCCTTTACAAAAGCGACTCATAGA

CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
pEVS170

TCTATGAGTCGCTTTTGTAAAGGAGTACGTTCGGCTGTCT

pEVS170

AGAACAAATACTAATCGTTGATATTTACAAAAGCGACTCATAG
A
TCTATGAGTCGCTTTTGTAAATATCAACGATTAGTATTTGTTCT

CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
pEVS170

GTTTCCGCCATTCTTTGGTGTCTTGATATGACTCCTT
AAGGAGTCATATCAAGACACCAAAGAATGGCGGAAAC

TGATACCCAGTCATAATAAATG
AGGTATTACTCAAGAAGGACTGT
GTTTCCGCCATTCTTTGAGTGTTAGTTATGTTATGTTGTTT
AAACAACATAACATAACTAACACTCAAAGAATGGCGGAAAC

TAGCGGTAGACACCAGCA
ATAACAACGGTTGATTTAATACTCTT
GTTTCCGCCATTCTTTGCTAACTCTGTTGAATGTAGG
CCTACATTCAACAGAGTTAGCAAAGAATGGCGGAAAC

pEVS170

GTTCTAACCATAGGACTGATTTACAAAAGCGACTCATAGA

CT4291
gDNA
CT4291
gDNA

TCTATGAGTCGCTTTTGTAAATCAGTCCTATGGTTAGAAC
ACCTTGCTCCTTAATTTGCCT

PrSEE63 674 85 SoAF

ORF76

PrSEE64 674 85 SoAR

ORF76

PrSEE65 674 85 SoBF

PrSEE67 674 85 SoCF

ErmR
cassette
ErmR
cassette
ORF76

PrSEE68 674 85 SoCR

ORF76

PrSEE55 674 90SoAF

ORF81

PrSEE56 674 90SoAR

ORF81

PrSEE57 674 90SoBF

G88SoCF

ErmR
cassette
ErmR
cassette
ORF81

G88SoCR2

ORF81

PrSEE66 674 85 SoBR

G88SoBR

Yeast Toxicity Assay
674_32YES FRBS

ORF32

674_32YES R

ORF32

PrSEE52 34YES FRBS2 631_674

ORF34

PrSEE53 34YES R2 631_674

ORF34

35YES F

ORF35

35YES R

ORF35

674_85 YES FRBS

ORF76

CT4291
gDNA
CT4291
gDNA
pEVS170

AAGGGCGTTATTGGAGG

pEVS170

TTTCTCGTCTGACTCAACTTTACAAAAGCGACTCATAGA

CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
pEVS170

TCTATGAGTCGCTTTTGTAAAGTTGAGTCAGACGAGAAA

pEVS170

GGATGTATTTCGGGTTGTTTACAAAAGCGACTCATAGA

CT4291
gDNA
CT4291
gDNA

TCTATGAGTCGCTTTTGTAAACAACCCGAAATACATCC

CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
CT4291
gDNA
CT4291
gDNA

AAAATGCCTATATCTTTAACCGGATGTTT

CGTTTCCGCCATTCTTTAATGATTTCCATACAGTTAGAGTC
GACTCTAACTGTATGGAAATCATTAAAGAATGGCGGAAACG

TCACCATAGCTGCGTTG
ATAGGCAGTTGAATGTTAAGTT
GTTTCCGCCATTCTTTGTATTAACATTTTTACCCA
TGGGTAAAAATGTTAATACAAAGAATGGCGGAAAC

GTTATTGACACTGATAGTGGCTT

TCAGTCCACTTCTGAATACAGTGTTTCTCTG
TTGATGGTTTGTTTTTCAGGTTTTTTC
TACAACTAGTCTCCAGCCTAATGTACCGT
GAAATGAGTATTATGATTCCTACATTCAACAGAG
CTAAAATCAAATCCTTTCTATCAATGTTCACT
GCTATGGCTTTAAATAAAATTAACTCTATTAACT

674_85YES R

ORF76

674_90YES FRBS

ORF81

674_90YES R

ORF81

Erm = erythromycin

CT4291
gDNA
CT4291
gDNA
CT4291
gDNA

CAGAAAATCTCTGCTAATGTAAAATTAACC
AAAATGGTAATACAAAGCCAAAAACTGAGA
TTACCATATAATACCATGTTCACGAAGTATA

CHAPTER IV: CONCLUSION
This study identified four effectors unique to VPaIß/γ and absent from the pandemic
VPaIα, and suggests that three alleles could contribute to the clinical success of tdh3-VPaIγ. The
most useful tool generated from this work is the construction of pSEElostfoX and the
corresponding rapid Vibrio natural transformation protocol. When in the presence of arabinose,
pSEElostfoX induces natural competence in V. parahaemolyticus and V. fischeri. This allows for
rapid transformation and genetic deletions in these species. This tool is to rapidly generate
mutations can hopefully be utilized in other Vibrio labs.
This work provides a series of eukaryotic models that can be used to evaluate the role of
T3SS effectors in V. parahaemolyticus. The S. cerevisiae toxicity model optimized in this study
can easily be utilized for other toxin identification for other bacteria and initial assessment due to
its ease of use, and rapid results. As exemplified by expression of the known effector VopZ, this
model does have limitations of evaluating toxins that elicit a singular cell effect. After multiple lab
members had trouble reproducing data from previous work 273, the A. castellanii co-culture model
optimized in this study can be used to evaluate individual effectors. G. mellonella is a popular
model to study bacterial virulence in the presence of an innate immune system such as pathogens
would experience during human infection. This model was developed for our V. parahaemolyticus
collection by Kara Rzasa as an undergraduate research project, before her graduation. We expect
to achieve a higher resolution of this model with further experiments and perhaps knockout of
hemolysin genes tdh and trh. The final eukaryotic model developed in this study was the use of
Caco-2 cells to assess the cytotoxic effect of T3SS toxins on human colon cells. Other Whistler
lab researchers have already used the protocol developed for this model. Future researchers can
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follow the progression through these eukaryotic models for their V. parahaemolyticus work, or
quickly adapt these to other bacteria as has already been done for V. fischeri work in the Whistler
lab.
Further characterization of the effectors is warranted to understand their contribution
towards infection and environmental persistence. The first step will be to assess if each of the
effectors is secreted by the T3SS 166. A secretion assay will also assess if differences in cytotoxicity
between tdh3-VPaIγ and tdh5-VPaIγ are related to differences in secretion rates of the effectors.
Scanning Electron Microscopy images of V. parahaemolyticus-induced effacement of the
enterocyte brush border with Caco-2BBe cells will visualize the V. parahaemolyticus infection
and evaluate if an effector contributes to the infection process. Further characterization of the
mucin-degradation potential of ORF34 is warranted. Co-culture with a mucus-producing cell line
such as HT29-MTX followed by an enzyme-linked immunosorbent assay (ELISA) could be used
to characterize this protein further. Finally, the use of the premier model for gastric infection, the
infant rabbit infection model, can truly assess whether the effectors play a role in gastric disease.
A better representation of environmental fitness would be the use of microcosms. Microcosms
with natural seawater would provide a more appropriate setting for assessment of V.
parahaemolyticus environmental fitness than the controlled settings in the A. castellanii model.
The blocks of homoplasy in the VPaIs (Figure 3.3) indicates that these islands are evolving
in geographic populations. Now present in the North Atlantic, it is likely that these four lineages
of VPaI will continue this geographic population evolution and begin to recombine with each
other. This work is important because if we can better understand the effector(s) that influence
environmental or clinical prevalence, we can identify not only if V. parahaemolyticus harbors
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tdh3-, tdh5-, tdh6-, or tdh7-VPaIγ, but as these islands evolve if they contain the effector allele
associated with enhanced virulence.
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